<SEC-DOCUMENT>0001193125-21-262153.txt : 20210831
<SEC-HEADER>0001193125-21-262153.hdr.sgml : 20210831
<ACCEPTANCE-DATETIME>20210831170107
ACCESSION NUMBER:		0001193125-21-262153
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20210831
DATE AS OF CHANGE:		20210831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ascendis Pharma A/S
		CENTRAL INDEX KEY:			0001612042
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256571
		FILM NUMBER:		211227635

	BUSINESS ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
		BUSINESS PHONE:		45 70 22 22 44

	MAIL ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d158006d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-256571<BR> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus supplement and the
accompanying prospectus is not complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying prospectus is an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or
sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#eb0029"><B>Subject to completion,
dated August&nbsp;31, 2021 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus supplement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To prospectus dated May&nbsp;27, 2021) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$400,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158006g01m54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>representing ordinary shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering $400,000,000 of
American Depositary Shares, or ADSs, representing ordinary shares of Ascendis Pharma A/S. Each ADS will represent one issued ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs,
representing our ordinary shares, are listed on The Nasdaq Global Select Market under the symbol &#147;ASND&#148;. On August&nbsp;30, 2021, the last reported sale price of the ADSs on The Nasdaq Global Select Market was $154.28 per ADS. Based on an
assumed public offering price of $154.28 per share, the last reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, we would expect to offer approximately 2,592,688 ADSs hereby. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Ascendis Pharma A/S, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;Underwriting&#148; for additional disclosure regarding the underwriting commissions and estimated
offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to an additional $60,000,000 of
ADSs from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in the ADSs involves a high degree of risk. See &#147;<A HREF="#supprom158006_8">Risk factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-17</FONT> of this prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission, any U.S. state
securities commission, the Danish Financial Supervisory Authority, nor any other foreign securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying
prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the ADSs to purchasers on or about September
&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Morgan&nbsp;Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>SVB&nbsp;Leerink</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of contents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_1">About this prospectus supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_2">Presentation of financial information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_3">Market, industry and other data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_4">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_5">Prospectus supplement summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_6">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_7">Summary consolidated financial data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_8">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_9">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_10">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_11">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_12">Capitalization and indebtedness</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_13">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_14">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_15">Exchange controls</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_16">Validity of the securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_17">Material changes</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_18">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_19">Enforcement of civil liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_20">Where you can find more information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_21">Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158006_22">Disclosure of commission position on indemnification for Securities Act liabilities
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_1">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_3">PRINCIPAL MARKETS FOR OUR ORDINARY SHARES AND THE ADSs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_5">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_6">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_8">DESCRIPTION OF OTHER SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_9">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_10">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_11">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_13">EXCHANGE CONTROLS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_15">MATERIAL CHANGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_17">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_18">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_19">EXPENSES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or make any representations other than those
contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use in connection with this offering. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus is an offer to sell only the ADSs offered hereby, but only under circumstances and in jurisdictions where
it is lawful to do so. The information contained in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering is current only as of their respective
dates. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus
supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering when making your investment decision. You should also read and consider the information in the documents we
have referred you to in the section of this prospectus supplement entitled &#147;Where you can find more information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering to sell, and
seeking offers to buy, ADSs only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement, the accompanying base prospectus and the offering of the ADSs in certain jurisdictions may be restricted by law.
Persons outside the United States who come into possession of this prospectus supplement, the accompanying base prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ADSs and the distribution of this
prospectus supplement and the accompanying base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of
an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of ADSs and also adds
to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus dated May&nbsp;27, 2021,
included in our registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256571)</FONT> that became effective automatically upon filing with the U.S. Securities and Exchange
Commission, or the SEC, along with the documents incorporated by reference, which provides more general information, some of which may not apply to this offering. To the extent the information contained in this prospectus supplement differs or
varies from the information contained in the accompanying prospectus or the documents incorporated by reference that were filed with the SEC before the date of this prospectus supplement, you should rely on the information in this prospectus
supplement. Generally, when we refer to the prospectus, we are referring to this prospectus supplement and the accompanying prospectus combined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we
refer to &#147;Ascendis,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean Ascendis Pharma A/S, and, as the context requires, our consolidated subsidiaries, unless otherwise specified. When
we refer to &#147;you,&#148; we mean the holders of our ordinary shares, or shares, or ADSs representing our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ascendis, TransCon,
Ascendis logo. Ascendis Pharma and SKYTROFA are our trademarks used in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus supplement and the accompanying prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering. These documents may also include trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our
trademarks and tradenames referred to in these documents appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to
indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain our books and records in euros and report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting
Standards Board, or IASB, and as adopted by the European Union. None of the consolidated financial statements incorporated by reference into this prospectus supplement were prepared in accordance with generally accepted accounting principles in the
United States. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_3"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus supplement and the
accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, contains estimates, projections and other information concerning our industry, our business and the markets for our product
candidates, including data regarding the total sales of product in those markets, the estimated patient population in those markets, their projected growth rates, the perceptions and preferences of patients and physicians regarding the disease
indications that we are pursuing or may pursue, as well as data regarding market research, estimates and forecasts prepared by our senior management. Information that is based on estimates, forecasts, projections, market research or similar
methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business,
market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not
expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition,
assumptions and estimates of our and our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially
from our assumptions and estimates. See also &#147;Special note regarding forward-looking statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, and any free writing
prospectus that we have authorized for use in connection with this offering contain forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our
business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; and
other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals for our product candidates, including our
expectations regarding approval of our Marketing Authorization Application for TransCon Growth Hormone, or TransCon hGH or lonapegsomatropin-tcgd; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of developing our product candidates or any other future product
candidates, and conducting preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our pursuit of oncology as our second of three independent therapeutic areas of focus, and our development of a
pipeline of product candidates related to oncology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential market size and the size of the patient populations for
lonapegsomatropin-tcgd and our other product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential advantages of lonapegsomatropin-tcgd and our other product candidates
over existing therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into new collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations with regard to the ability to develop additional product candidates using our TransCon
technologies and file Investigational New Drug Applications, or INDs, or similar for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations with regard to the ability to seek expedited regulatory approval pathways for our product
candidates, including the potential ability to rely on the parent drug&#146;s clinical and safety data with regard to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations with regard to our current and future collaboration partners to pursue the development of our
product candidates and file INDs or similar for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our development plans with respect to lonapegsomatropin-tcgd and our other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of lonapegsomatropin-tcgd and our other product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities of lonapegsomatropin-tcgd and our other product
candidates and associated devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business, lonapegsomatropin-tcgd and our
other product candidates and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering
lonapegsomatropin-tcgd and our other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our
ability to obtain additional capital; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects on our business, operating results, prospects and financial condition of the worldwide <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on senior management&#146;s current
expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our
forward-looking statements in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering may turn out to be
inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk factors&#148; and elsewhere in this prospectus supplement. Potential investors are urged to
consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this prospectus supplement. Except as required by law, we assume no obligation to update or revise these
forward-looking statements for any reason, even if new information becomes available in the future. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events. You should,
however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus supplement. See &#147;Where you can find more information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_5"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary provides a general overview of selected information and does not contain all of the information you should consider before buying the ADSs.
Therefore, you should read the entire prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the information incorporated by reference,
before deciding to invest in the ADSs. Investors should carefully consider the information set forth under &#147;Risk factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-17</FONT> of this prospectus supplement and incorporated by
reference to our annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed on March&nbsp;10, 2021. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are applying our innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company and develop a pipeline of product
candidates with potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> profiles to address unmet medical needs. We currently have a pipeline of multiple independent endocrinology rare disease and
oncology product candidates in development. We are also working to apply our TransCon technology platform in additional therapeutic areas to address unmet medical needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;25, 2021, the FDA approved SKYTROFA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (lonapegsomatropin-tcgd) for the treatment of
pediatric patients one year and older who weigh at least 11.5&nbsp;kg (25.4&nbsp;lb) and have growth failure due to inadequate secretion of endogenous growth hormone. We also have submitted a regulatory application for marketing approval for
lonapegsomatropin-tcgd for the treatment of pediatric growth hormone deficiency, or GHD, in September 2020 to the European Medicines Agency, or EMA. Our initial U.S. commercial organization is in place to enable the U.S. launch of SKYTROFA and we
are beginning to build up our commercial organization outside of the United States for territories we plan to commercialize with our own sales organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, we <FONT STYLE="white-space:nowrap">co-founded</FONT> VISEN Pharmaceuticals, or VISEN, a company established to develop and commercialize our
endocrinology rare disease therapies in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan, or Greater China. We received 50% ownership in the outstanding shares of VISEN and concurrently with the rights we granted to VISEN for
lonapegsomatropin-tcgd, TransCon PTH (palopegteriparatide) and TransCon CNP. Entities affiliated with Vivo Capital and Sofinnova Ventures purchased shares in VISEN for an aggregate purchase price of $40&nbsp;million in cash. On January&nbsp;8, 2021,
we completed an equity investment of $12.5&nbsp;million in VISEN as part of VISEN&#146;s $150&nbsp;million Series&nbsp;B financing. Following VISEN&#146;s Series&nbsp;B financing round, we retained approximately 44% of VISEN&#146;s issued and
outstanding shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TransCon technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
TransCon technologies are designed to solve the fundamental limitations of previous approaches applied to extend the duration of a drug&#146;s action in the body, and to enhance the overall benefit of a given therapeutic. Many drugs suffer from
suboptimal pharmacokinetics, short residence time in the body, poor tolerability at the administration site and/or systemic side effects that result from initial drug concentrations that are too high. Frequent administration and poor tolerability
negatively impact patient compliance, potentially leading to suboptimal treatment outcomes. To address these issues, several approaches are currently being applied to improve drug characteristics, such as prodrug and sustained release technologies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TransCon technologies combine the benefits of conventional prodrug and sustained release technologies to create new therapies with potentially
optimized therapeutic effect, including efficacy, safety and dosing frequency. We believe the technologies can be applied broadly to a protein, peptide, antibody or small molecule in multiple therapeutic areas. TransCon molecules have three
components: an existing parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release
manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. Depending upon the type of TransCon carrier we employ, we can design our TransCon prodrugs to act systemically or locally in areas that are
difficult to treat with conventional therapies. In addition to retaining the original mode of action of the unmodified parent drug, we believe this predictable release may improve the likelihood of clinical development success. We refer to our
systemic and localized applications of TransCon as individual technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lonapegsomatropin-tcgd </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lonapegsomatropin-tcgd is an investigational once-weekly prodrug designed to deliver somatropin over a <FONT STYLE="white-space:nowrap">one-week</FONT> period.
The released somatropin has the same 191 amino acid sequence as daily somatropin. Lonapegsomatropin-tcgd is approved in the United States under the brand name SKYTROFA for the treatment of pediatric patients one year and older who weigh at least
11.5&nbsp;kg (25.4&nbsp;lb) and have growth failure due to inadequate secretion of endogenous growth hormone. Lonapegsomatropin-tcgd is under review by the EMA as a once-weekly treatment for pediatric GHD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SKYTROFA <FONT STYLE="white-space:nowrap">single-use,</FONT> prefilled cartridges will be available in the United States in nine dosage strengths, allowing
for convenient dosing flexibility. They are designed for use only with the SKYTROFA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;Auto-Injector and may be stored at room temperature for up to six months. The recommended dose of
SKYTROFA for <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients and patients switching from daily somatropin is 0.24&nbsp;mg/kg body weight, administered once weekly. Somatropin released from SKYTROFA produces a dose linear <FONT
STYLE="white-space:nowrap">IGF-1</FONT> response and the dosage of SKYTROFA may be individualized and titrated based on patient response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the body, a
similar distribution pattern as observed for daily somatropin is expected once somatropin is released from lonapegsomatropin-tcgd. We used daily growth hormone as an active comparator in our clinical studies, allowing us to directly compare the
activity of lonapegsomatropin-tcgd to daily growth hormone in an identical clinical setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our phase 3 pediatric program for lonapegsomatropin-tcgd
includes the heiGHt, fliGHt and enliGHten Trials. The heiGHt Trial was a randomized, open label, active-controlled phase 3 registrational trial that enrolled 161&nbsp;children with GHD who had not previously been treated. The fliGHt Trial was
designed to evaluate lonapegsomatropin-tcgd in subjects who were primarily treatment experienced with daily somatropin, although a subgroup of younger subjects were <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve.</FONT> Nearly all subjects
who completed the heiGHt or fliGHt Trials have enrolled in the open-label extension trial, or the enliGHten Trial, which is designed to provide long-term safety data to support regulatory submissions for lonapegsomatropin-tcgd. We initiated the
enliGHten Trial in 2017 as the first subjects began to roll over from the heiGHt Trial, and we have enrolled approximately 300&nbsp;pediatric subjects. Data from the enliGHten Trial formed the long-term safety database supporting our Biologics
License Application submission to the FDA for lonapegsomatropin-tcgd for the treatment of pediatric GHD which was approved in August 2021, as well as the submission of an MAA to the EMA, which occurred in September 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, in January 2021, we announced a <FONT STYLE="white-space:nowrap">104-week</FONT> analysis of data from the ongoing enliGHten Trial, including <FONT
STYLE="white-space:nowrap">follow-up</FONT> on subjects from the heiGHt Trial who continued into the enliGHten Trial. The data showed maintenance of a treatment advantage in subjects initially treated with lonapegsomatropin-tcgd beyond the first
year of therapy. The safety results, which were comparable to Genotropin in the phase 3 heiGHt Trial, were consistent across the phase&nbsp;3 clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, we filed a Clinical Trial Notification, or CTN, with the Pharmaceuticals and Medical Devices Agency, or PMDA, in Japan, to initiate our
phase 3 riGHt Trial of lonapegsomatropin-tcgd for the </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment for pediatric GHD. The primary objective of the riGHt Trial is to evaluate and compare the AHV of 40 Japanese prepubertal <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT>
children with GHD treated with weekly lonapegsomatropin-tcgd to that of a commercially available daily somatropin formulation at 52&nbsp;weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July
2020, the EMA adopted a decision agreeing with the positive opinion from the Paediatric Development Committee, or PDCO, which approved the proposed Paediatric Investigation Plan, or PIP, for lonapegsomatropin-tcgd. The PDCO endorsed the
lonapegsomatropin-tcgd program as acceptable for assessment of safety and efficacy for the use of lonapegsomatropin-tcgd as a treatment for GHD in children from six months to less than 18 years of age, mirroring the population covered by the studies
conducted in the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, we received orphan drug designation from the FDA for lonapegsomatropin-tcgd in the United States for the
treatment of GHD. The FDA grants orphan designation to drugs that are intended for the treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States, and potentially may be safer or more
effective than already approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2019, we received orphan designation from the European Commission, or EC, for lonapegsomatropin-tcgd
for GHD. Orphan designation is granted to therapies aimed at the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating, affects no more than five in 10,000 persons in the European Union and for which no
satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would provide significant additional benefit over existing therapies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have initiated the foresiGHt Trial, a global phase&nbsp;3 study with the aim to demonstrate the metabolic benefits of lonapegsomatropin-tcgd
in adults with GHD, and in Greater China, VISEN completed the patient enrollment of <FONT STYLE="white-space:nowrap">154&nbsp;treatment-na&iuml;ve,</FONT> prepubertal children for the ongoing phase&nbsp;3 pivotal trial of lonapegsomatropin-tcgd in
patients with pediatric GHD in March 2021. We intend to pursue other indications for lonapegsomatropin-tcgd consistent with our strategy to create sustainable growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Palopegteriparatide </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are using our TransCon technology
platform to develop palopegteriparatide, an investigational once-daily long-acting prodrug of parathyroid hormone, or PTH, as a potential treatment for adult hypoparathyroidism, or HP, a rare endocrine disorder of calcium and phosphate metabolism.
Palopegteriparatide is designed to replace PTH at physiologic levels for 24 hours each day to address both the short-term symptoms and long-term complications of HP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current standard of care, or SoC, for HP patients primarily consists of active vitamin D and oral calcium supplementation. However, since PTH is not
present at the kidney to facilitate calcium reabsorption from the urine, the goal of SoC is to maintain serum calcium, or sCa, levels just below or within the lower part of the normal range and thereby limit as much as possible the damage from
excess urinary calcium. Nonetheless, SoC frequently leads to significant sCa fluctuations accompanied by symptomatic hyper- or hypocalcemia. SoC with active vitamin D and calcium have been shown to contribute to the risk of renal disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HP also poses a high burden on the healthcare system despite current SoC. For example, one survey of 374 patients showed that 72% experienced more than ten
symptoms in the preceding twelve months, with symptoms experienced for a mean of 13 &plusmn; 9 hours a day. Other studies showed that 79% of HP cases require hospitalizations and that patients with the disease have a four-fold increase in the risk
of renal disease compared to healthy controls. Patients often experience decreased quality of life. We conducted a survey of 42 patients which found that 100&nbsp;percent of subjects reported negative psychological impacts, interference with daily
life and impact on physical functioning from HP, and that 76&nbsp;percent were either no longer able to work or experienced interference with work productivity. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palopegteriparatide is currently in phase 3 development as a treatment for adult HP. In September 2020, we
submitted an amendment to our IND to initiate PaTHway, our North American and European phase 3 double-blinded, placebo controlled clinical trial evaluating the safety, tolerability and efficacy of palopegteriparatide in adults with HP following
discussions with FDA and European regulatory authorities. On July&nbsp;6, 2021, we announced that the PaTHway Trial reached the target enrollment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, on July&nbsp;6, 2021, we announced the receipt of orphan drug designation for palopegteriparatide from the Japanese Ministry of Health, Labor, and Welfare. Furthermore, we announced the acceptance of the CTN for the PaTHway Japan Trial, <FONT
STYLE="white-space:nowrap">a&nbsp;single-arm,&nbsp;phase</FONT> 3 trial of palopegteriparatide in a minimum of 12 Japanese subjects with HP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;2, 2021, VISEN announced IND approval from the Center for Drug Evaluation on the National Medical Products Administration for the phase&nbsp;3 clinical trial of palopegteriparatide in adult subjects with HP, the PaTHway China Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;10, 2021, we announced <FONT STYLE="white-space:nowrap">preliminary&nbsp;58-week&nbsp;results</FONT> from the continuing open-label extension, or
OLE, portion of the PaTH Forward Trial, a global phase 2 trial evaluating the safety, tolerability, and efficacy of its investigational product candidate, palopegteriparatide, in adult subjects with HP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key Findings of the Preliminary OLE Results of PaTH Forward Trial at 58 weeks </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">58 subjects continued in the open-label extension beyond 58 weeks </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued treatment with palopegteriparatide demonstrated that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">91% of subjects were off SoC therapy defined as no active vitamin D and less than or equal to 600 mg/day of
calcium supplements </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Urinary calcium maintained in the normal range </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bone markers trended towards the <FONT STYLE="white-space:nowrap">mid-normal</FONT> levels </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quality of life benefits measured by <FONT STYLE="white-space:nowrap">SF-36</FONT> continued within normal range
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Palopegteriparatide was well-tolerated at all doses administered </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events led to
discontinuation of study drug </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No change to the safety profile in the OLE portion of the study </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of August&nbsp;23, 2021, 58 subjects were continuing in the OLE portion of the PaTH Forward Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2020, the EC granted orphan designation to palopegteriparatide for the treatment of HP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, we reported data from the four-week fixed dose, blinded portion of PaTH Forward Trial <FONT STYLE="white-space:nowrap">on&nbsp;SF-36</FONT><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;Health Survey which demonstrated that palopegteriparatide significantly improved quality of life and restored physical and mental functioning toward a normal level compared to placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, we reported <FONT STYLE="white-space:nowrap">positive&nbsp;top-line&nbsp;results</FONT> from the four-week fixed dose, blinded portion of our
phase 2 PaTH Forward Trial, which evaluated the safety, tolerability and efficacy of three fixed doses of palopegteriparatide using <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;ready-to-use&nbsp;prefilled</FONT></FONT>
pen injector planned for commercial presentation. The goal of PaTH Forward was to identify a starting dose for a pivotal phase 3 trial, establish a titration regimen for complete withdrawal of standard of care (i.e., active vitamin D and calcium
supplements), and evaluate palopegteriparatide </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control of serum and urinary calcium. A total of 59 subjects were randomized in a blinded manner to receive fixed doses of palopegteriparatide at 15, 18 or 21 &micro;g/day or placebo for four
weeks. All doses of palopegteriparatide were well-tolerated, and no serious or severe adverse events were observed during this period. No treatment-emergent adverse events, or TEAEs, led to discontinuation of study drug, and the overall incidence of
TEAEs was comparable between palopegteriparatide and placebo. Additionally, there were no drop-outs during the four-week fixed dose period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2018,
we were granted orphan drug designation by the FDA for palopegteriparatide for the treatment of hypoparathyroidism. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">TransCon&nbsp;C-Type&nbsp;Natriuretic</FONT> Peptide </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TransCon <FONT STYLE="white-space:nowrap">C-Type</FONT> Natriuretic Peptide, or TransCon CNP, is an investigational long-acting prodrug of CNP designed to
provide continuous CNP exposure at therapeutic levels with a well-tolerated and convenient once-weekly dose. It is being developed for the treatment of children with achondroplasia. TransCon CNP is designed to provide effective shielding of CNP from
neutral endopeptidase degradation in subcutaneous tissue and the blood compartment, minimize binding of CNP to <FONT STYLE="white-space:nowrap">the&nbsp;NPR-C&nbsp;receptor</FONT> to decrease clearance, reduce binding of CNP to <FONT
STYLE="white-space:nowrap">the&nbsp;NPR-B&nbsp;receptor</FONT> in the cardiovascular system to avoid hypotension, and release unmodified CNP, which is small enough in size to allow effective penetration into growth plates. We believe TransCon CNP
offers advantages over short-acting CNP and CNP analogs in development that result in high Cmax levels which may cause adverse cardiovascular events. In addition, we expect a more constant CNP exposure at lower Cmax to contribute to better
therapeutic outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2019, we initiated the phase 2 ACcomplisH Trial to evaluate safety and efficacy of TransCon CNP in children <FONT
STYLE="white-space:nowrap">(ages&nbsp;2-10&nbsp;years)</FONT> with achondroplasia. In collaboration with VISEN, we are sponsoring the ACcomplisH China Trial, a randomized, double-blind, placebo-controlled, phase 2 dose expansion trial to evaluate
the safety and efficacy of TransCon CNP in subjects with achondroplasia. The primary endpoint is to evaluate the safety of treatment and its effect <FONT STYLE="white-space:nowrap">on&nbsp;12-month&nbsp;annualized</FONT> height velocity. In January
2021, China Center for Drug Evaluation of National Medical Products Administration approved VISEN&#146;s IND application to conduct the ACcomplisH China Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2020, we received orphan designation from the EC for TransCon CNP for treatment of achondroplasia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2019, we were granted orphan drug designation by the FDA for TransCon CNP for the treatment of achondroplasia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, we reported preliminary results from a phase 1 trial in healthy adult subjects, which we believe supported our target product profile for
TransCon CNP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TransCon product candidates within oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, we established oncology as our second independent therapeutic area of focus for our TransCon technologies. Our goal is to improve treatment
efficacy while limiting or reducing toxicity by applying TransCon technologies to clinically validated drugs, using our unique algorithm for product innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are conducting preclinical studies within the field of oncology to explore multiple potential product candidates and evaluate systemic as well as localized
delivery systems using our TransCon technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently advancing two product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TransCon TLR7/8 Agonist is designed for sustained release of TLR7/8 agonist, resiquimod, and intended for
intratumoral administration. This product candidate is designed to provide potent </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
activation of the innate immune system in the tumor and draining lymph nodes and to have low risk of systemic toxicity. In December 2020, we filed an IND with the FDA to initiate the clinical
program of TransCon TLR7/8 Agonist with the <FONT STYLE="white-space:nowrap">transcendIT-101</FONT> Trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TransCon <FONT STYLE="white-space:nowrap">IL-2</FONT> &szlig;/<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> is
designed for prolonged exposure of an <FONT STYLE="white-space:nowrap">IL-2</FONT> variant that selectively activates the <FONT STYLE="white-space:nowrap">IL-2R&szlig;/</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>, with minimal binding to <FONT
STYLE="white-space:nowrap">IL-2R&#945;.</FONT> This product candidate is designed to provide potent anti-tumor activity and to have reduced risk of toxicity, such as vascular leak syndrome. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are evaluating additional TransCon product candidates in nonclinical research studies for the treatment of a variety of tumor types. Examples of TransCon
product candidates under evaluation include stimulators of innate and adaptive immunity, as well as modulators of the tumor microenvironment. We are exploring systemic and intratumoral administration both as a monotherapy and as a component of
combination regimens. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TransCon product candidate pipeline </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158006g19v99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FDA approved on August&nbsp;25, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In development in Greater China through strategic investment in VISEN Pharmaceuticals. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Japanese riGHt Trial. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Global foresiGHt Trial. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">North American and European PaTHway Trial, Japanese PaTHway Japan Trial. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">North America, Europe, and Oceania ACcomplisH Trial. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TranscendIT-101. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;25, 2021, we
announced that the FDA approved SKYTROFA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due
to inadequate secretion of endogenous growth hormone. As a once-weekly injection, SKYTROFA is the first FDA approved product that delivers somatropin (growth hormone) by sustained release over one week. The approval includes the new SKYTROFA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Auto-Injector and cartridges which, after first removed from a refrigerator, allow families to store the medicine at room temperature for up to six months. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were organized under the laws of the Kingdom of Denmark in September 2006 as a private limited liability company (<I>Anpartsselskab</I>, or ApS) and then
transformed into a public limited liability company (<I>Aktieselskab</I>, or A/S), effective December&nbsp;17, 2007. In connection with this conversion, our legal name changed from Ascendis Pharma ApS to Ascendis Pharma A/S. We commenced operations
in December 2007 in connection with the acquisition of the company that invented our TransCon technologies, Complex Biosystems GmbH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered
office and principal executive offices are located at Tuborg Boulevard 12, <FONT STYLE="white-space:nowrap">DK-2900</FONT> Hellerup, Denmark and our telephone number is +45 70 22 22 44. Our agent for service of process in the United States is
Ascendis Pharma, Inc. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_6"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ADSs offered by us </P></TD>
<TD>2,592,688 ADSs, representing 2,592,688 ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares to be outstanding after this offering </P></TD>
<TD>56,493,678 ordinary shares (including 2,592,688 ordinary shares represented by the 2,592,688 ADSs issued in this offering) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ADSs </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to an additional 388,903 ADSs. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares </P></TD>
<TD>Each ADS will represent one ordinary share, nominal value DKK 1 per share. As an ADS holder you will not be treated as one of our shareholders and you will not have shareholder rights. You will have the rights of an ADS holder as provided in the
deposit agreement among us, the depositary and owners and holders of ADSs from time to time. To better understand the terms of the ADSs, you should carefully read the section of the accompanying prospectus entitled &#147;Description of American
Depositary Shares&#148; and the deposit agreement incorporated by reference into the registration statement of which this prospectus supplement forms a part. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>The Bank of New York Mellon </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $379.3&nbsp;million, or approximately $436.3&nbsp;million if the underwriters exercise their option to purchase additional ADSs in full, after deducting the estimated
underwriting commissions and estimated offering expenses payable by us, based on an assumed public offering price of $154.28 per ADS, the last reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021. We currently
expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to support the commercial preparations, launch and commercial activities, clinical development and regulatory approval
for lonapegsomatropin-tcgd, to fund clinical development of our other endocrinology rare disease programs, including palopegteriparatide and TransCon CNP, to identify and progress development of new product candidates, including in the therapeutic
area of oncology, and for working capital and other general corporate purposes. See &#147;Use of proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk factors&#148; and other information included in this prospectus supplement for a discussion of factors that you should consider carefully before deciding to invest in the ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ASND&#148; </TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of ordinary shares to be outstanding after this offering is based on 53,900,990 ordinary shares
outstanding as of June&nbsp;30, 2021, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,065,823 ordinary shares issuable upon exercise of outstanding warrants at a weighted-average exercise price of
&#128;71.04 per share ($84.42), as of June&nbsp;30, 2021 (based on the exchange rate reported by the European Central Bank on June&nbsp;30, 2021); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,603,979 ordinary shares issuable upon exercise of warrants that we are authorized to issue in the future, as of
June&nbsp;30, 2021, of which 122,165 warrants have been issued after June&nbsp;30, 2021 at a weighted-average exercise price of &#128;105.33 per share ($125.18 per share) (based on the exchange rate reported by the European Central Bank on
June&nbsp;30, 2021). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus supplement reflects an assumed public
offering price of $154.28 per ADS, which was the last reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, and assumes no exercise of the underwriters&#146; option to purchase additional ADSs and no exercise of
outstanding warrants. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_7"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present summary consolidated financial data for our business. We derived the summary consolidated statement of profit or loss and other
comprehensive income data for the years ended December&nbsp;31, 2020, 2019 and 2018 from our audited consolidated financial statements incorporated by reference into this prospectus supplement. We derived the summary consolidated statement of profit
or loss and other comprehensive income data for the six months ended June&nbsp;30, 2021 and 2020 and the summary consolidated statement of financial position as of June&nbsp;30, 2021 from our unaudited condensed consolidated interim financial
statements incorporated by reference into this prospectus supplement. We maintain our books and records in euros, and prepare our audited consolidated financial statements in accordance with IFRS as issued by the IASB and as adopted by the European
Union and our unaudited condensed consolidated interim financial statements in accordance with International Accounting Standard 34, Interim Financial Reporting. The following information should be read in conjunction with our audited consolidated
financial statements and unaudited condensed consolidated interim financial statements and related notes, as well as the information under the captions &#147;Item 5. Operating and Financial Review and Prospects&#148; appearing in our Annual Report
on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2020 and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; appearing in Exhibit 99.2 of our Report on Form
<FONT STYLE="white-space:nowrap">6-K</FONT> filed with the SEC on August&nbsp;27, 2021, which are incorporated by reference herein. For more details on how you can obtain our reports and other information filed with the SEC, you should read the
section of this prospectus supplement and the accompanying prospectus entitled &#147;Where you can find more information.&#148; Our historical results are not necessarily indicative of our future results, and our interim period results are not
necessarily indicative of results to be expected for a full year or any other interim period. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary consolidated statement of profit or loss and other comprehensive income data: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(EUR &#146;000, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(191,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,669)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,473)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,057)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,591)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,720)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating profit / (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(330,620</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(226,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(154,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(242,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(156,152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share of profit / (loss) of associate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,842)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,221)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,703)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(876)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Profit / (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(419,174</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(130,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(197,425</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax on profit / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net profit / (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(418,955)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,016)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(130,097)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(197,166)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,249)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income / (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Items that may be reclassified subsequently to profit or loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences on translating foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income / (loss) for the period, net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(61)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income / (loss) for the period, net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(418,997</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,053</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(130,080</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(195,401</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,310</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit / (loss) for the period attributable to owners of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(418,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive income / (loss) for the period attributable to owners of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(418,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>EUR</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>EUR</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>EUR</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>EUR</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>EUR</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted earnings/(loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares used for calculation (basic and diluted)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,616,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,506,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,085,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,804,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,096,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A total of 6,148,004, 5,820,211, 5,611,629, 6,065,823 and 5,788,390 warrants outstanding as of
December&nbsp;31, 2020, December&nbsp;31, 2019, December&nbsp;31, 2018, June&nbsp;30, 2021 and June&nbsp;30, 2020, respectively, can potentially dilute earnings per share in the future, but have not been included in the calculation of diluted
earnings per share because they are antidilutive for the periods presented. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary consolidated statement of financial position
data: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below presents summary unaudited condensed consolidated interim statement of financial position data as of June&nbsp;30, 2021: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to give effect to the sale of 2,592,688 ADSs in this offering based on an assumed public
offering price of $154.28 per ADS, the last reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,173,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributable equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,733,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,054,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,227,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,227,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A $1.00 increase or decrease in the assumed public offering price of $154.28 per ADS, which is the last
reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, would increase or decrease, as applicable, the as adjusted amount of each of cash, cash equivalents and marketable securities, total assets, share premium
and total equity by approximately $2.5&nbsp;million, assuming that the number of ADSs offered by us (based on the assumed public offering price of $154.28 per ADS) remains the same and after deducting the estimated underwriting commissions and
estimated offering expenses payable by us. An increase or decrease of 100,000 in the number of ADSs we are offering would increase or decrease, as applicable, the as adjusted amount of each of cash, cash equivalents and marketable securities, total
assets, share premium and total equity by approximately $14.7&nbsp;million, assuming that the assumed public offering price remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_8"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in the ADSs involves a high degree of risk. You should consider carefully the risks described below and discussed in our Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> filed on March&nbsp;10, 2021, which is incorporated by reference in this prospectus supplement in its entirety, together with other information in this prospectus supplement, the accompanying prospectus and the
information and documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest
in the ADSs. If any of the following events actually occurs, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of the ADSs to decline and you may lose all
or part of your investment. The risks described below and incorporated by reference in this prospectus supplement and the accompanying prospectus are not the only ones that we face. Additional risks not presently known to us or that we currently
deem immaterial may also affect our business operations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks relating to this offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our senior management team may invest or spend the net proceeds of this offering in ways with which you may not agree or in ways which may not yield a
significant return. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our senior management will have broad discretion over, and we could spend, the net proceeds from this offering in ways with
which the holders of ordinary shares or ADSs may not agree or that do not yield a favorable return, if any. We currently expect to use our existing cash, cash equivalents and marketable securities and the net proceeds from this offering to support
the commercial preparations, launch and commercial activities, clinical development and regulatory approval for lonapegsomatropin-tcgd, to fund clinical development of our other endocrinology rare disease programs, including palopegteriparatide and
TransCon CNP, to identify and progress development of new product candidates, including in the therapeutic area of oncology, and for working capital and general corporate purposes. However, our senior management will have considerable discretion in
the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not improve
our operating results or enhance the value of our ordinary shares or ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution in the net
tangible book value per ADS of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price per ADS being offered is higher than the net tangible book value per ADS outstanding
prior to this offering. As a result, investors purchasing ADSs in this offering will incur immediate dilution of $133.32 per ADS, based on an assumed public offering price of $154.28 per ADS, which was the last reported sale price of the ADSs on The
Nasdaq Global Select Market on August&nbsp;30, 2021 and our as adjusted net tangible book value per ADS as of&nbsp;June 30, 2021, after giving effect to this offering and the assumed offering price. For information on how the foregoing amounts were
calculated, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This dilution is due to the substantially lower price paid by our investors who purchased ordinary shares or ADSs
prior to this offering as compared to the price offered to the public in this offering. As a result of the dilution to investors purchasing ADSs in this offering, investors may receive significantly less than the purchase price paid in this
offering, if anything, in the event of our liquidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional ordinary shares, ADSs or other securities convertible into or exchangeable for our
ordinary shares. We cannot assure you that we will be able to sell ordinary shares, ADSs or other securities in any other offering at a price per share that is equal to or greater than the price per ADS paid by investors in this offering, and
investors purchasing ordinary shares, ADSs or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional ordinary shares, ADSs or other securities convertible into or
exchangeable for our ordinary shares in future transactions may be higher or lower than the price per ADS in this offering. As of June&nbsp;30, 2021, approximately 8.7&nbsp;million ordinary shares that are either subject to outstanding warrants or
reserved for future issuance under our warrant incentive program are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of the ADSs may be volatile and the holders of the ADSs may not be able to resell ADSs at or above the price they paid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of the ADSs could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our
control. These factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results from, or any delays in, clinical trial programs relating to our product candidates, including clinical
trials for lonapegsomatropin-tcgd, palopegteriparatide and TransCon CNP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects on our business, operating results, prospects and financial condition of the worldwide <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to apply our TransCon technologies to therapeutic areas other than endocrinology, including the
therapeutic area of oncology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize or obtain regulatory approval for our product candidates, or delays in
commercializing or obtaining regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of regulatory approval or a complete response letter to our product candidates, or specific label
indications or patient populations for its use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to current or future collaborations or joint ventures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of therapeutic innovations or new products by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements regarding the parent drugs that we use in developing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse actions taken by regulatory authorities with respect to our clinical trials, manufacturing supply chain
or sales and marketing activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or developments in laws or regulations applicable to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse changes to our relationship with any manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our efforts to acquire, license or discover additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement actions in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning our competitors or the pharmaceutical industry in general; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of expected product sales and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture, supply or distribution shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EMA, FDA or other similar regulatory actions affecting us or our industry or other healthcare reform measures in
the European Union, United States or in other markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates or recommendations by securities analysts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of the ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of ordinary shares and/or ADSs by us, our senior management and board members, holders of the ADSs or our
shareholders in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions and overall fluctuations in the United States and international equity
markets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the loss of any of our key scientific or senior management personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced
extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of ADSs. In the past, when the market price of a stock has been volatile,
holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of ordinary shares or ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit
and the attention of our senior management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a &#147;passive foreign investment company&#148; for U.S. federal income tax purposes for our current taxable year and future taxable years,
which could result in adverse U.S. federal income tax consequences to U.S. investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Internal Revenue Code of 1986, as amended, the
determination of passive foreign investment company, or PFIC, status is fact-specific, and generally cannot be made until after the close of the taxable year in question. Based on the market price of our ADSs, the value of our assets and the
composition of our income and assets, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December&nbsp;31, 2020. However, the application of the PFIC rules is subject to uncertainty in several respects,
and we cannot assure you we will not be a PFIC for any taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation will be considered a
PFIC for any taxable year if either (1)&nbsp;at least 75% of its gross income for such year is passive income or (2)&nbsp;at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets) during such year
is attributable to assets that produce or are held for the production of passive income. A separate determination must be made each taxable year as to whether we are a PFIC (after the close of each such taxable year). If we are a PFIC for any
taxable year during which a U.S. Holder (as defined in &#147;Taxation&#151;Material U.S. federal income tax consequences to U.S. holders&#148;) holds ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences, including
(i)&nbsp;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&nbsp;the application of an interest charge with respect to such gain and certain dividends and (iii)&nbsp;compliance with certain reporting requirements.
Although we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended December&nbsp;31, 2020, the application of the PFIC rules is subject to uncertainty in several respects. Whether we will be a PFIC in any year
depends on the composition of our income and assets, and the relative fair market value of our assets from time to time, which we expect may vary substantially over time. Among other things, because (i)&nbsp;we currently own a significant amount of
passive assets, including cash, cash equivalents and marketable securities, and (ii)&nbsp;the value of our assets (including our intangible assets) that generate <FONT STYLE="white-space:nowrap">non-passive</FONT> income for PFIC purposes is
uncertain and may vary substantially over time, we cannot assure you we will not be a PFIC for any tax year. Each U.S. Holder is strongly urged to consult its tax advisor regarding these issues. See &#147;Taxation&#151;Material U.S. federal income
tax consequences to U.S. holders.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of our ordinary shares or ADSs, such holder may
be subject to adverse U.S. federal income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder (as defined in &#147;Taxation&#151;Material U.S. federal income tax
consequences to U.S. holders&#148;) is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares or ADSs, such U.S. Holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any). Because our group
includes one or more U.S. subsidiaries, certain of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries will be treated as &#147;controlled foreign corporations&#148; (regardless of whether we are treated as a &#147;controlled foreign
corporation&#148;). A &#147;United States shareholder&#148; of a &#147;controlled foreign corporation&#148; may be required to report annually and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global
intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S. property by &#147;controlled foreign corporations,&#148; regardless of whether we make any distributions. Failure to comply with these reporting
obligations may subject a &#147;United States shareholder&#148; to significant monetary penalties and may prevent the statute of limitations from starting with respect to such shareholder&#146;s U.S. federal income tax return for the year for which
reporting was due. Further, an individual that is a &#147;United States shareholder&#148; with respect to a &#147;controlled foreign corporation&#148; generally would not be allowed certain tax deductions or foreign tax credits that would be allowed
to a &#147;United States shareholder&#148; that is a U.S. corporation. We cannot provide any assurances that we will assist investors in determining whether any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries are treated as a
&#147;controlled foreign corporation&#148; or whether such investor is treated as a &#147;United States shareholder&#148; with respect to any of such &#147;controlled foreign corporations.&#148; Further, we cannot provide any assurances that we will
furnish to any &#147;United States shareholders&#148; information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of
these rules to their investment in our ordinary shares or ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_9"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of 2,592,688 ADSs in this offering will be approximately $379.3&nbsp;million (or approximately
$436.3&nbsp;million if the underwriters exercise their option to purchase an additional 388,903 ADSs in full), based on an assumed public offering price of $154.28 per ADS, which was the last reported sale price of the ADSs on The Nasdaq Global
Select Market on August&nbsp;30, 2021, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. A $1.00 increase or decrease in the assumed public offering price of $154.28 per ADS, which was the last
reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, would increase or decrease, as applicable, the net proceeds to us by approximately $2.5&nbsp;million, assuming that the number of ADSs offered by us (based
on the assumed public offering price of $154.28 per ADS) remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ADSs we are offering.
An increase or decrease of 100,000 in the number of ADSs we are offering would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $14.7&nbsp;million, assuming that the assumed public offering price
remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to use the
net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to support the commercial preparations, launch and commercial activities, clinical development and regulatory approval for
lonapegsomatropin-tcgd, to fund clinical development of our other endocrinology rare disease programs, including palopegteriparatide and TransCon CNP, to identify and progress development of new product candidates, including in the therapeutic area
of oncology, and for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our planned use of our net proceeds from this offering, we currently
estimate that such funds, together with existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong,
and we could use these available capital resources sooner than we currently expect. It is possible that we will not achieve the progress that we expect because the actual costs and timing of drug development, including obtaining regulatory
approvals, and of commercialization preparations are difficult to predict and are subject to substantial risks and delays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the uncertainties
inherent in the clinical development, regulatory approval and commercialization process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. As such, our senior
management will retain discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors, including unforeseen delays or problems in the clinical development, regulatory
approval or commercialization process and in the development of our manufacturing and supply chain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_10"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our share capital. We intend to retain all available funds and any future earnings, if any, to fund the
development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_11"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Danish tax considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion
describes the material Danish tax consequences under present law of an investment in the ADSs (representing our ordinary shares). The summary is for general information only and does not purport to constitute exhaustive tax or legal advice. It is
specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. The summary is based solely on the tax laws of Denmark in effect on the date of this prospectus supplement. Danish tax laws may
be subject to change, possibly with retroactive effect. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The summary does not cover investors to whom special tax rules apply, and, therefore, may not
be relevant, for example, to investors subject to the Danish Tax on Pension Yields Act (<I>i.e.</I>, pension savings), professional investors, certain institutional investors, insurance companies, pension companies, banks, stockbrokers and investors
with tax liability on return on pension investments. The summary does not cover taxation of individuals and companies who carry on a business of purchasing and selling shares. The summary only sets out the tax position of the direct owners of the
ADSs and further assumes that the direct investors are the beneficial owners of the ADSs and any dividends thereon. Sales are assumed to be sales to a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potential investors in the ADSs are advised to consult their tax advisors regarding the applicable tax consequences of acquiring, holding and disposing of the
ADSs based on their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who may be affected by the tax laws of other jurisdictions should consult their tax advisors with
respect to the tax consequences applicable to their particular circumstances as such consequences may differ significantly from those described herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Danish tax resident holders of the ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is currently not clear under the Danish tax legislation or case law how the listed ADSs are to be treated for tax purposes, and therefore no level of
assurance can be given on this matter. For the purpose of the below comments, it is assumed that a holder of ADSs listed in the U.S. should be treated as holding <FONT STYLE="white-space:nowrap">non-listed</FONT> shares in the company, as the
company&#146;s ordinary shares are not admitted to trading on a regulated market. However, recent communications from the Danish Tax authorities indicate that based on an individual analysis based on the actual facts and circumstances and terms and
conditions of the depositary agreement, a holder of ADS&#146;s may not be treated as holding unlisted shares in the company for Danish tax purposes, which has hitherto been assumed when the underlying asset consists of an unlisted share.
Furthermore, the communications from the Danish Tax authorities indicate if the holders of ADSs are not treated as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company
for Danish tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the tax position and treatment of ADSs under Danish law are still unclear. In the event that the holders of ADSs are
not treated as holding unlisted shares in the company, it is likely that they will be treated as either holding listed shares or financial instruments for tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, the below summary assumes that the holders of ADSs listed in the U.S. should be treated as holding unlisted ordinary shares in the company
for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale of the ADSs (individuals) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For individual investors
in 2021, gains from the sale of shares are included in the computation of the annual share income subject to 27% tax on the first DKK 56,500 (for cohabiting spouses, a total of DKK 113,000) and at a </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate of 42% on share income exceeding DKK 56,500 (for cohabiting spouses over DKK 113,000). Such amounts are subject to annual adjustment and include all share income (i.e., all capital gains and
dividends derived by the individual or cohabiting spouses, respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gains and losses on the sale of shares are calculated as the difference between
the purchase price and the sales price. The purchase price is generally determined using the average method (in Danish &#147;<I>gennemsnitsmetoden</I>&#148;) as a proportionate part of the aggregate purchase price for all the shareholder&#146;s
shares in the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the ADSs, for the purpose of this tax description, are considered unlisted shares for Danish tax purposes, losses may be offset
against other share income (<I>i.e.</I>, received dividends and capital gains on the sale of shares). Unused losses will automatically be offset against a cohabiting spouse&#146;s share income. In case the share income becomes negative, a negative
tax on the share income will be calculated and offset against the individual&#146;s other final taxes. Unused negative tax on share income will be offset against a cohabiting spouse&#146;s final taxes. If the negative tax on share income cannot be
offset against a cohabiting spouse&#146;s final taxes, the negative tax can be carried forward indefinitely and offset against future year&#146;s taxes. The tax treatment follows from the realization principle. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale of the ADSs (companies) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of taxation
of sales of shares made by shareholders (companies), a distinction is made between Subsidiary Shares, Group Shares, <FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> Portfolio Shares and Taxable Portfolio Shares (note that the ownership threshold
described below is applied on the basis of the number of all shares issued by the company, and not on the basis of the number of the ADSs issued): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>Subsidiary Shares</I>&#148; are generally defined as shares owned by a shareholder holding at least 10% of the nominal share capital of the issuing
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>Group Shares</I>&#148; are generally defined as shares in a company in which the shareholder of the company and the issuing company are
subject to Danish joint taxation or fulfill the requirements for international joint taxation under Danish law (<I>i.e.</I>, the company is controlled by the shareholder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I><FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> Portfolio Shares</I>&#148; are defined as shares not admitted to trading on a regulated market
owned by a shareholder holding less than 10% of the nominal share capital of the issuing company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>Taxable Portfolio Shares</I>&#148; are defined
as shares that do not qualify as Subsidiary Shares, Group Shares or <FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> Portfolio Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gains or losses
on disposal of Subsidiary Shares and Group Shares and <FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> Portfolio Shares are not included in the taxable income of the shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special rules apply with respect to Subsidiary Shares and Group Shares to prevent exemption through certain holding company structures just as other
anti-avoidance rules may apply. These rules will not be described in further detail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital gains from the sale of Taxable Portfolio Shares are taxable
at a rate of 22% irrespective of ownership period. Losses on such shares are generally deductible. Gains and losses on Taxable Portfolio Shares are generally taxable according to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> principle (in Danish &#147;<I>lagerprincippet</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> principle, each year&#146;s taxable gain or
loss on Taxable Portfolio Shares is calculated as the difference between the market value of the shares at the beginning and end of the tax year. Thus, taxation will take place on an accrual basis even if no shares have been disposed of and no gains
or losses have been realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Taxable Portfolio Shares are sold or otherwise disposed of before the end of the income year, the
taxable income of that income year equals the difference between the value of the Taxable Portfolio Shares at the beginning of the income year and the value of the Taxable Portfolio Shares at realization. If the Taxable Portfolio Shares are acquired
and realized in the same income year, the taxable income equals the difference between the acquisition sum and the realization sum. If the Taxable Portfolio Shares are acquired in the income year and not realized in the same income year, the taxable
income equals the difference between the acquisition sum and the value of the shares at the end of the income years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change of status from Subsidiary
Shares/Group <FONT STYLE="white-space:nowrap">Shares/Tax-Exempt</FONT> Portfolio Shares to Taxable Portfolio Shares (or vice versa) is for tax purposes deemed to be a disposal of the shares and a reacquisition of the shares at market value at the
time of change of status. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends (individuals) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, it is uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is
highly uncertain if the actual distribution of dividends on ADSs to Danish investors are considered dividends for Danish tax purposes. However, if such distributions to Danish tax resident individual investors are treated as dividends, taxation as
share income, as described above, will take place. All share income must be included when calculating whether the amounts described above are exceeded. Dividends paid to individuals are generally subject to 27% withholding tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends (companies) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For corporate investors, dividends
paid (subject to the same uncertainty as described immediately above) on Subsidiary Shares and Group Shares are <FONT STYLE="white-space:nowrap">tax-exempt</FONT> irrespective of ownership period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid on <FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> Portfolio Shares are partly taxable as 70% of the dividends received are included in the
taxable income, which is equivalent to an effective taxation of 15.4% (70% of 22%) irrespective of ownership period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid on Taxable Portfolio
Shares are subject to the standard corporation tax rate of 22% irrespective of ownership period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual withholding tax rate is as a starting point
27%, while it can be reduced (0%, 15.4%, 22%) if certain requirements are met. A claim for repayment can be made within two months or the excess tax will offset the corporation income tax for the year. The statute of limitations is three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of shareholders residing outside Denmark </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is currently not clear under the Danish tax legislation or case law how the listed ADSs are to be treated for tax purposes, and therefore no level of
assurance can be given on this matter. For the purpose of this summary, it is assumed that a holder of ADSs listed in the U.S. should be treated as holding <FONT STYLE="white-space:nowrap">non-listed</FONT> shares in the company, as the
company&#146;s ordinary shares are not admitted to trading on a regulated market. However, recent communications from the Danish Tax authorities indicate that based on an individual analysis based on the actual facts and circumstances and terms and
conditions of the depositary agreement, a holder of ADS&#146;s may not be treated as holding unlisted shares in the company for Danish tax purposes, which has hitherto been assumed when the underlying asset consists of an unlisted share.
Furthermore, the communications from the Danish Tax authorities indicate if the holders of ADSs are not treated as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company
for Danish tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the tax position and treatment of ADSs under Danish law are still unclear. In the event that the holders of ADSs are
not treated as holding unlisted shares in the company it is likely that they will be treated as either holding listed shares or financial instruments for tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, the below summary assumes that the holders of ADSs listed in the U.S. should be treated
as holding unlisted ordinary shares in the company for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of
ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale of the ADSs (individuals and companies) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the ADSs not resident in Denmark are normally not subject to Danish taxation on any gains realized on the sale of ADSs, irrespective of the
ownership period, subject to certain anti-avoidance rules seeking to prevent that taxable dividend payments are converted to tax exempt capital gains. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
Danish share transfer tax or stamp duties are payable on transfer of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an investor holds the ADSs in connection with a trade or business conducted
from a permanent establishment in Denmark, gains on shares may be included in the taxable income of such activities pursuant to the rules applying to Danish tax residents as described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends (individuals) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, it is
uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is highly uncertain if the holders of ADSs are entitled to apply for a refund of Danish withholding tax on dividends
paid by the company. If the holders of ADSs are not entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the depository bank may according to the recent communications from the Danish Tax authorities in
certain circumstances be entitled to apply for a refund of Danish withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if the holders of ADSs for Danish purposes are treated as
holders of the ordinary shares in the company and are entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the below should apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to individuals are generally subject to 27% withholding tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-residents</FONT> of Denmark are not subject to additional Danish income tax in respect to dividends received on shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the holders of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax
residence country of ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For holders of ADSs (as beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final
tax rate (as reduced according to domestic law or an applicable double tax treaty) for the holder of ADSs, a request for a refund of Danish tax in excess hereof can be made in the following situations: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reduction according to a tax treaty </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that
the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the
applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States, Switzerland and almost all members of the European Union. The tax treaty between Denmark and the
United States generally provides for a 15% tax rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reduction according to Danish tax law </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the
ADSs issued) of the company and the ADS holder is tax resident in a state which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax matters according to which the competent authority in
the state of the ADS holder is obligated to exchange information with Denmark, dividends are subject to tax at a rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15%
tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that the reduced tax
rate does not affect the withholding rate, which is why the holder must claim a refund as described above in order to benefit from the reduced rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a <FONT STYLE="white-space:nowrap">non-resident</FONT> of Denmark holds shares which can be attributed to a permanent establishment in Denmark,
dividends are taxable pursuant to the rules applying to Danish tax residents described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends (companies) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, it is uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is
highly uncertain if the holders of ADSs are entitled to apply for a refund of Danish withholding tax on dividends paid by the company. If the holders of ADSs are not entitled to apply for a refund of Danish withholding tax on dividends paid by the
company, then the depository bank may according to the recent communications from the Danish Tax authorities in certain circumstances be entitled to apply for a refund of Danish withholding tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, if the holders of ADSs for Danish purposes are treated as holders of the ordinary shares in the company and are entitled to apply for a refund of
Danish withholding tax on dividends paid by the company, then the below should apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to companies are generally subject to 27%
withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-residents</FONT> of Denmark are not subject to additional income tax with respect to dividends
received on shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the investors of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between
Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors (as beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate
(as reduced according to domestic law or an applicable double tax treaty) for the investor, a request for a refund of Danish tax in excess hereof can be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends from Subsidiary Shares are tax exempt provided that the taxation of the dividends is to be waived or reduced in accordance with the
Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the jurisdiction in which the company investor is resident. If Denmark is to reduce taxation of dividends to a foreign company under a tax treaty, Denmark will
not&#151;as a matter of domestic law&#151;exercise such right and will in general not impose any tax at all. Further, dividends from Group Shares&#151;not also being Subsidiary Shares&#151;are exempt from Danish tax provided the company investor is
a resident of the European Union or the EEA and provided the taxation of dividends should have been waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the country in which the
company investor is resident had the shares been Subsidiary Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid on both <FONT STYLE="white-space:nowrap">Tax-Exempt</FONT> and Taxable Portfolio Shares are
generally subject to tax at a rate of 22% irrespective of ownership period. While the actual withholding tax rate is as a starting point 27%, it can be reduced if certain requirements are met. If the withholding tax rate applied is higher than the
applicable final tax rate for the ADS holder, a request for a refund of Danish tax in excess hereof can be made by the ADS holder in the following situations: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reduction according to a tax treaty </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that
the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the
applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States and almost all members of the European Union. The tax treaty between Denmark and the United States
generally provides for a 15% rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reduction according to Danish tax law </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the
ADSs issued) in the company and the ADS holder is resident in a jurisdiction which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax according to which the competent authority in the
state of the ADS holder is obligated to exchange information with Denmark, dividends are generally subject to a tax rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the
15% tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company. Note that the reduced tax rate does not affect the withholding rate, hence, in this situation the ADS holder must
also in this situation claim a refund as described above in order to benefit from the reduced rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a
<FONT STYLE="white-space:nowrap">non-resident</FONT> company of Denmark holds ADSs which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share transfer tax and stamp duties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Danish share
transfer tax or stamp duties are payable on transfer of the shares or ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. federal income tax consequences to U.S. holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in
the ADSs. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws, the alternative minimum tax or the Medicare contribution tax on net investment income, are not discussed. This summary
applies only to investors who hold the ADSs as capital assets (generally, property held for investment) and who have the U.S. dollar as their functional currency. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the
Code, U.S. Treasury regulations promulgated thereunder, or the Treasury Regulations, judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the income tax treaty between the
United States and Denmark, or the Treaty, all as in effect as of the date of this prospectus supplement. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion does not address all U.S. federal income tax consequences relevant to a U.S. Holder&#146;s particular circumstances or to
U.S. Holders subject to particular rules, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding the ADSs as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, commodities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships, S corporations or other entities or arrangements treated as partnerships or pass-through entities
for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired the ADSs pursuant to the exercise of any employee share option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own 10% or more of our equity by vote or value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold their ADSs through a permanent establishment or fixed base outside the United States; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell the ADSs under the constructive sale provisions of the Code. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS
THE U.S. STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE ADSs. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of the ADSs that, for U.S. federal income tax purposes, is or is treated as
any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized under the laws of the United
States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the supervision of a U.S. court and the control of one or more &#147;United
States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a partner in a partnership (or other entity or arrangement taxable as a partnership for U.S. federal income tax purposes)
that holds the ADSs, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding the ADSs and the partners in such partnerships should consult their tax advisors regarding the U.S. federal
income tax consequences applicable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion below assumes that the representations contained in the deposit agreement are true and that
the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for the U.S. federal income tax purposes as holding the ordinary shares
represented by the ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer
of the security underlying the ADS may be taking actions that are inconsistent with the beneficial ownership of the underlying security. Accordingly, the creditability of foreign taxes, if any, as described below, could be affected by actions taken
by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of such actions the holders of ADSs are not properly treated as beneficial owners of underlying ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of dividends and other distributions on the ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, the gross amount of any distribution to you with respect to the ADSs will be included in your gross income as
dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent the amount of the
distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in the ADSs, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital
gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect a distribution will generally be reported as ordinary dividend income for such purposes. Any dividends will
not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are
eligible for benefits under the Treaty, or if the ADSs are readily tradable on an established securities market in the United States, dividends a U.S. Holder receives from us generally will be &#147;qualified dividend income.&#148; If certain
holding period and other requirements, including a requirement that we are not a PFIC in the year of the dividend or the immediately preceding year, are met, qualified dividend income of an individual or other
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder generally will be subject to preferential tax rates. ADSs representing ordinary shares generally are considered for these purposes to be readily tradable on an established securities
market in the United States if they are listed on The Nasdaq Global Select Market, as our ADSs are. You should consult your tax advisor regarding the availability of these preferential tax rates under your particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in &#147;Taxation&#151;Danish tax considerations,&#148; payments of dividends by us may be subject to Danish withholding tax. The rate of
withholding tax applicable to U.S. Holders that are eligible for benefits under the Treaty is reduced to a maximum of 15%. For U.S. federal income tax purposes, U.S. Holders will be treated as having received the amount of withheld Danish taxes, and
as then having paid over the withheld taxes to the Danish taxing authorities. As a result of this rule, the amount of dividend income included in gross income for U.S. federal income tax purposes by a U.S. Holder with respect to a payment of
dividends may be greater than the amount of cash actually received (or receivable) by the U.S. Holder from us with respect to the payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends will
generally constitute foreign source income for foreign tax credit limitation purposes. Subject to the discussion of the PFIC rules below, any tax withheld with respect to distributions on the ADSs at the rate applicable to a U.S. Holder may, subject
to a number of complex limitations, be claimed as a foreign tax credit against such U.S. Holder&#146;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal income tax purposes. Any amounts withheld in excess of the tax
rate applicable to a U.S. Holder generally is not eligible to be claimed as a foreign tax credit, regardless of whether such amounts are actually refunded or reclaimed. The limitation on foreign taxes eligible for credit is calculated separately
with respect to specific classes of income. For this purpose, dividends distributed by us with respect to the ADSs generally will constitute &#147;passive category income.&#148; The rules with respect to the foreign tax credit are complex and
involve the application of rules that depend upon a U.S. Holder&#146;s particular circumstances. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of disposition of the ADSs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to
the PFIC rules discussed below, you will recognize gain or loss on any sale, exchange or other taxable disposition of an ADS equal to the difference between the amount realized (in U.S. dollars) on the disposition of the ADS and your tax basis (in
U.S. dollars) in the ADS. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if you have held the ADS for more than one year at the time of sale, exchange or other taxable disposition. Otherwise, such gain
or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders, including individuals, generally will be taxable at a reduced rate. The deductibility
of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. You should consult your tax advisor regarding the proper treatment
of gain or loss in your particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive foreign investment company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Internal Revenue Code of 1986, as amended, the determination of passive foreign investment company, or PFIC, status is fact-specific, and generally
cannot be made until after the close of the taxable year in question. Based on the market price of the ADSs and the value and composition of our income and assets, we do not believe we were a PFIC for U.S. federal income tax purposes for our taxable
year ended December&nbsp;31, 2020. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure you we will not be a PFIC for any taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is considered a PFIC for any taxable year if either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 75% of its gross income for such taxable year is passive income, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets)
during such taxable year is attributable to assets that produce or are held for the production of passive income. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the
above calculations, if a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, it will be treated as if it (a)&nbsp;held a
proportionate share of the assets of such other corporation and (b)&nbsp;received directly a proportionate share of the income of such other corporation. Passive income generally includes dividends, interest, rents, royalties and capital gains, but
generally excludes rents and royalties which are derived in the active conduct of a trade or business and which are received from a person other than a related person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A separate determination must be made each taxable year as to whether we are a PFIC (after the close of each such taxable year). Because the value of our
assets for purposes of the asset test will generally be determined by reference to the market price of the ADSs, our PFIC status will depend in large part on the market price of the ADSs, which may fluctuate significantly. In addition, changes in
the composition of our income or assets may cause us to become a PFIC. Among other things, because (i)&nbsp;we currently own a significant amount of passive assets, including cash, cash equivalents and marketable securities, and (ii)&nbsp;the value
of our assets (including our intangible assets) that generate <FONT STYLE="white-space:nowrap">non-passive</FONT> income for PFIC purposes is uncertain and may vary substantially over time, we cannot assure you we will not be a PFIC for any tax
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any year during which you hold the ADSs, we generally will continue to be treated as a PFIC with respect to you for all
succeeding years during which you hold the ADSs, regardless of whether we continue to meet the income or asset tests described above, unless we cease to be a PFIC and you make a &#147;deemed sale&#148; election with respect to the ADSs you hold. If
such election is made, you will be deemed to have sold the ADSs you hold at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences
described below. After the deemed sale election, the ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each taxable year we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any &#147;excess
distribution&#148; (as defined below) you receive and any gain you realize from a sale or other disposition (including a pledge) of the ADSs, unless you make a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you
received during the shorter of the three preceding taxable years or your holding period for the ADSs will be treated as an &#147;excess distribution.&#148; Under these special tax rules, if you receive any &#147;excess distribution&#148; or realize
any gain from a sale or other disposition of the ADSs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#147;excess distribution&#148; or gain will be allocated ratably over your holding period for the ADSs,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year, and any taxable year before the first taxable year in your
holding period in which we were a PFIC, will be treated as ordinary income , and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each other year will be subject to the highest income tax rate in effect for that year
and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gains (but not losses) realized on the sale of the ADSs cannot be treated as capital, even if you hold the ADSs as capital assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are treated as a PFIC with respect to you for any taxable year, to the extent we own directly or indirectly equity in any foreign corporations that are
also PFICs, you will be deemed to own your proportionate share of any such lower-tier PFIC, and you may be subject to the rules described in the preceding two paragraphs with respect to the shares of such lower-tier PFICs you would be deemed to own.
As a result, you may incur liability for any &#147;excess distribution&#148; described above if we receive a distribution from such lower-tier PFICs or if any shares in such lower-tier PFICs are disposed of (or deemed disposed of). You should
consult your tax advisor regarding the application of the PFIC rules to any lower-tier PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, a U.S. Holder of &#147;marketable
stock&#148; (as defined below) in a PFIC may make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election for such stock to elect out of the general tax treatment for PFICs discussed
above. If you make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election for the ADSs, you will include in income for each year we are a PFIC an amount equal to the excess, if any, of
the fair market value of the ADSs as of the close of your taxable year over your adjusted basis in such ADSs. You are allowed a deduction for the excess, if any, of the adjusted basis of the ADSs over their fair market value as of the close of the
taxable year. However, deductions are allowable only to the extent of any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> gains on the ADSs included in your income for prior taxable
years. Amounts included in your income under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election, as well as gain on the actual sale or other disposition of the ADSs, are treated as
ordinary income. Ordinary loss treatment also applies to the deductible portion of any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> loss on the ADSs, as well as to any loss realized on
the actual sale or disposition of the ADSs to the extent the amount of such loss does not exceed the net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> gains previously included for the
ADSs. Your basis in the ADSs will be adjusted to reflect any such income or loss amounts. If you make a valid <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election, the tax rules that
apply to distributions by corporations that are not PFICs would apply to distributions by us, except the lower applicable tax rate for qualified dividend income would not apply. If we cease to be a PFIC when you have a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election in effect, gain or loss realized by you on the sale of the ADSs will be a capital gain or loss and taxed in the manner described
above under &#147;&#151;Taxation of disposition of the ADSs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election is available only for &#147;marketable stock,&#148; which is stock that is traded in other than <I>de minimis</I> quantities on at
least 15 days during each calendar quarter, or regularly traded, on a qualified exchange or other market, as defined in applicable Treasury Regulations. Any trades that have as their principal purpose meeting this requirement will be disregarded.
The ADSs are listed on The Nasdaq Global Select Market and, accordingly, provided the ADSs are regularly traded, if you are a holder of ADSs, the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election would be available to you if we are a PFIC. Once made, the election cannot be revoked without the consent of the IRS unless the ADSs
cease to be &#147;marketable stock.&#148; If we are a PFIC for any year in which the U.S. Holder owns ADSs but before a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election is made, the
interest charge rules described above will apply to any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> gain recognized in the year the election is made. The
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election may not be available with respect to the shares of lower-tier PFICs that are treated as owned by you. Consequently, you could be
subject to the PFIC rules with respect to income of the lower-tier PFICs the value of which already had been taken into account indirectly via <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT>
adjustments. A U.S. Holder should consult its tax advisors as to the availability and desirability of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election, as well as the impact of
such election on interests in any lower-tier PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain circumstances, a U.S. Holder of stock in a PFIC can make a &#147;qualified electing
fund&#148; election to mitigate some of the adverse tax consequences of holding stock in a PFIC by including in income its share of the corporation&#146;s income on a current basis. However, we do not currently intend to prepare or provide the
information that would enable you to make a &#147;qualified electing fund&#148; election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an
annual report containing such information as the U.S. Treasury may require. A U.S. Holder&#146;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#146;s U.S. federal income tax return to remain open with
regard to the items required to be included in such report until three years after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S.
Holder&#146;s entire U.S. federal income tax return will remain open during such period. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules, taking into account the
uncertainty as to whether we are currently treated as or may become a PFIC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>YOU ARE STRONGLY URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE
APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT IN THE ADSs. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information reporting and backup withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend payments with respect to the ADSs and proceeds from the sale, exchange or other disposition of the ADSs may be subject to information reporting to the
IRS and U.S. backup withholding. Certain U.S. Holders are exempt from backup withholding, including corporations and certain <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations. A U.S. Holder will be subject to backup withholding if
such holder is not otherwise exempt and such holder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fails to furnish the holder&#146;s taxpayer identification number, which for an individual is ordinarily his or
her social security number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnishes an incorrect taxpayer identification number; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification
number and that the IRS has not notified the holder that the holder is subject to backup withholding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against the U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S.
Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional reporting requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax return
disclosure obligations (and related penalties for failure to disclose) apply to certain U.S. Holders who hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes
not only financial accounts maintained in foreign financial institutions, but also may include the ADSs. U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_12"></A>CAPITALIZATION AND INDEBTEDNESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of June&nbsp;30, 2021(1): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to give further effect to the issuance of 2,592,688 ADSs, representing 2,592,688 ordinary
shares, in this offering based on (i)&nbsp;an assumed public offering price of $154.28 per ADS, the last reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, after deducting the estimated underwriting
commissions and estimated offering expenses payable by us and (ii)&nbsp;the exchange rate reported by the European Central Bank on August&nbsp;30, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this information together with our audited consolidated financial statements and unaudited condensed consolidated interim financial statements
and related notes, each incorporated by reference into this prospectus supplement. For more details on how you can obtain our SEC reports and other information, you should read the section of the prospectus entitled &#147;Where you can find more
information.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>adjusted(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributable equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,733,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,054,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,227,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,227,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since June&nbsp;30, 2021, on July&nbsp;13, 2021 and August&nbsp;10, 2021, we granted warrants to subscribe for
an aggregate of 122,165 of our ordinary shares to our employees and other service providers. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A $1.00 increase or decrease in the assumed public offering price of $154.28 per ADS, which is the last
reported sale price of the ADSs on The Nasdaq Global Select Market on August&nbsp;30, 2021, would increase or decrease, as applicable, the as adjusted amount of each of cash, cash equivalents and marketable securities, equity, share capital, share
premium, total equity and total capitalization by approximately $2.5&nbsp;million, assuming that the number of ADSs offered by us (based on the assumed public offering price of $154.28 per ADS) remains the same and after deducting the estimated
underwriting commissions and estimated offering expenses payable by us. An increase or decrease of 100,000 in the number of ADSs we are offering would increase or decrease, as applicable, the as adjusted amount of each of cash, cash equivalents and
marketable securities, equity, share capital, share premium, total equity and total capitalization by approximately $14.7&nbsp;million, assuming that the assumed public offering price remains the same and after deducting the estimated underwriting
commissions and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding share capital and distributable equity information in the table above, as of
June&nbsp;30,&nbsp;2021, excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,065,823 ordinary shares issuable upon exercise of outstanding warrants at a weighted-average exercise price of
&#128;71.04 per share ($84.42), as of June&nbsp;30, 2021 (based on the exchange rate reported by the European Central Bank on June&nbsp;30, 2021); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,603,979 ordinary shares issuable upon exercise of warrants that we are authorized to issue in the future, as of
June&nbsp;30, 2021, of which 122,165 warrants have been issued after June&nbsp;30, 2021 at a weighted-average exercise price of &#128;105.33 per share ($125.18 per share) (based on the exchange rate reported by the European Central Bank on
June&nbsp;30, 2021). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_13"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in the ADSs in this offering, your interest will be immediately diluted to the extent of the difference between the public offering price per
ADS in this offering and the net tangible book value per ADS after this offering. As of June&nbsp;30, 2021, we had a historical net tangible book value of $804.8&nbsp;million, or $14.93 per ADS. Our net tangible book value represents total
consolidated tangible assets less total consolidated liabilities and our net tangible book value per ADS represents the net tangible book value, all divided by the number of ordinary shares outstanding on June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of the ADSs in this offering based on (i)&nbsp;the last reported sale price of the ADSs on The Nasdaq Global Select Market on
August&nbsp;30, 2021, of $154.28 per ADS and (ii)&nbsp;the exchange rate reported by the European Central Bank on August&nbsp;30, 2021, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us, our as
adjusted net tangible book value at June&nbsp;30, 2021 would have been approximately $1,184.1&nbsp;million, or $20.96 per ADS. This represents an immediate increase in as adjusted net tangible book value of $6.03 per ADS to existing shareholders and
holders of ADSs and an immediate dilution in net tangible book value of $133.32 per ADS to new investors purchasing the ADSs in this offering. The following table illustrates this per ADS dilution: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per ADS as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.93</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per ADS attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per ADS as of June&nbsp;30, 2021, after giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per ADS to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters fully exercise their option to purchase additional ADSs, as adjusted net tangible book value as of
June&nbsp;30, 2021 after this offering would increase to approximately $21.82 per ADS, and there would be an immediate dilution of approximately $132.46 per ADS to new investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed public offering price of $154.28 per ADS, which is the last reported sale price of the ADSs on The Nasdaq Global
Select Market on August&nbsp;30, 2021, would increase (decrease) the as adjusted net tangible book value as of June&nbsp;30, 2021 by approximately $2.5&nbsp;million, or approximately $0.04 per ADS, and increase (decrease) the dilution per ADS to new
investors by approximately $0.04 per ADS, assuming that the number of ADSs offered by us (based on the assumed public offering price of $154.28 per ADS) remains the same and after deducting the estimated underwriting commissions and estimated
offering expenses payable by us. An increase (decrease) of 100,000 in the number of ADSs we are offering would increase (decrease) the as adjusted net tangible book value by approximately $14.7&nbsp;million, or $0.26 per ADS, and would decrease
(increase) the dilution per ADS to new investors by approximately $0.26 per ADS, assuming that the assumed public offering price remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by
us. The as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding warrants are exercised, investors purchasing the ADSs in this offering will experience further dilution. In addition, we may
choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders and the holders of ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations (other than the historical net tangible book value calculations) are
based on 53,900,990 ordinary shares outstanding as of June&nbsp;30, 2021, and excludes the following, in each case as of such date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,065,823 ordinary shares issuable upon exercise of outstanding warrants at a weighted-average exercise price of
&#128;71.04 per share ($84.42), as of June&nbsp;30, 2021 (based on the exchange rate reported by the European Central Bank on June&nbsp;30, 2021); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,603,979 ordinary shares issuable upon exercise of warrants that we are authorized to issue in the future, as of
June&nbsp;30, 2021, of which 122,165 warrants have been issued after June&nbsp;30, 2021 at a weighted-average exercise price of &#128;105.33 per share ($125.18 per share) (based on the exchange rate reported by the European Central Bank on
June&nbsp;30, 2021). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_14"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering the ADSs described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC, Morgan Stanley&nbsp;&amp; Co.
LLC, Evercore Group L.L.C. and SVB Leerink LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and
conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting commissions set forth on the cover page of this
prospectus supplement, the number of ADSs listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all of the ADSs offered by us if they purchase any ADSs. The underwriting agreement
also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any purchases of ADSs by the underwriters pursuant to the underwriting agreement are carried out by the underwriters agreeing, severally and not jointly, to
subscribe for ordinary shares and deposit such ordinary shares with the depositary, receiving in return the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the
ADSs directly to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. After the initial offering of the ADSs to the public, the offering price and other selling terms may be changed by the underwriters. Sales of ADSs made outside of the
United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs from us. The underwriters have 30&nbsp;days from the date of this prospectus supplement to exercise this option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs. If any ADSs are purchased with this option to purchase additional ADSs, the underwriters will purchase ADSs in approximately the same proportion as shown in
the table above. If any additional ADSs are purchased, the underwriters will offer the additional ADSs on the same terms as those on which the ADSs are being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per ADS less the amount paid by the underwriters to us per ADS. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. The following table shows the per ADS and total underwriting commissions to be paid to the underwriters assuming both no exercise and full exercise of the
underwriters&#146; option to purchase additional ADSs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>option to<BR>purchase<BR>additional<BR>ADSs&nbsp;exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With full<BR>option to<BR>purchase<BR>additional<BR>ADSs&nbsp;exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal
and accounting expenses, but excluding the underwriting commissions, will be approximately $750,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed to reimburse the underwriters for up to $20,000 of expenses relating to clearance of
this offering with the Financial Industry Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by
one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of ADSs to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed that we will not, and will not publicly disclose an intention to, subject to limited exceptions, (i)&nbsp;directly or indirectly, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend or otherwise transfer or dispose of any ADSs, ordinary shares or any
securities convertible into or exercisable or exchangeable for ADSs or ordinary shares (collectively, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;) or submit or file any registration statement under the Securities Act
with respect to any of the foregoing, or (ii)&nbsp;enter into any swap, hedging or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of ADSs, ordinary shares or other securities, in cash or otherwise, in each case
without the prior written consent of J.P.&nbsp;Morgan Securities LLC, Morgan Stanley&nbsp;&amp; Co. LLC, Evercore Group L.L.C. and SVB Leerink LLC for a period of 45 days after the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to: (i)&nbsp;the sale of the ADSs to the underwriters; (ii)&nbsp;the issuance
by us of ADSs or ordinary shares upon the exercise of an option or a warrant or the conversion of a security outstanding on the date of this prospectus supplement and described herein or in the documents incorporated by reference; (iii)&nbsp;the
issuance by us of ADSs or ordinary shares granted pursuant to our existing employee benefit plans described herein or in the documents incorporated by reference; (iv)&nbsp;the issuance by us of ADSs or ordinary shares pursuant to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director equity plan or dividend reinvestment plan described herein or in the documents incorporated by reference; (v)&nbsp;the filing by us of any registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto; or (vi)&nbsp;the issuance by us of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with a transaction with any third party that includes a bona fide
commercial relationship with us (including any joint venture, marketing or distribution arrangement, strategic alliance, collaboration agreement or corporate partnering or intellectual property license agreement with us); provided, however, that the
aggregate number of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities issued pursuant to such issuances during the period of 45 days after the date of this prospectus supplement shall not exceed 10% of the total number of ordinary shares
issued and outstanding immediately following the issuance and sale of the ADSs pursuant to this prospectus supplement, and provided, further that we shall cause each recipient of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities issued
pursuant to such issuances during the period of 45 days after the date of this prospectus supplement to enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters in the same form entered into by our directors and
executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and executive officers have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters prior to the commencement of this offering pursuant to which each of these persons, with limited exceptions, for a period of 45 days after the date of this prospectus supplement, may not, without the prior written consent of J.P. Morgan
Securities LLC, Morgan Stanley&nbsp;&amp; Co. LLC, Evercore Group L.L.C. and SVB Leerink LLC, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, hedge, lend or otherwise transfer or dispose of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or exercise any right with respect to the registration of any of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, (ii)&nbsp;enter into any hedging, swap or any other agreement or any transaction that
transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery of ADSs, ordinary
shares or other securities, in cash or otherwise, or (iii)&nbsp;publicly disclose the intention to do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to, among other things and
subject to certain conditions and exceptions, transfers or dispositions: (i)&nbsp;as a bona fide gift or gifts, sale or other dispositions or distributions among the securityholder or family members of the securityholder, or to affiliates of the
securityholder, (ii)&nbsp;to any trust for direct or indirect benefit of the securityholder or immediate family of the securityholder; (iii)&nbsp;by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or family member of the securityholder; (iv)&nbsp;transfers or dispositions that occur by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement; (v)&nbsp;distributions to limited
partners or shareholders of the securityholder; (vi)&nbsp;resulting from the exercise of warrants or other securities convertible or exercisable for ADSs or ordinary shares granted pursuant to our equity incentive plans; (vii)&nbsp;the establishment
of any contract, instruction or plan that satisfies the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the E Securities Exchange Act of 1934, as amended, or the Exchange Act, provided no sales of any securities will occur
during the lockup period; (viii)&nbsp;any demands or requests for, the exercise of any right with respect to, or any action in preparation of, the registration by us of the securityholder&#146;s ADSs or ordinary shares, provided no transfer of such
securities will be made during the lockup period; (ix)&nbsp;transfers of our securities pursuant to agreements under which we have the option to repurchase such securities from the securityholder or the Company has a right of first refusal with
respect to transfers of such securities; (x)&nbsp;transfers pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of ADSs or ordinary shares involving a change of control of our
company; (xi)&nbsp;transfers of securities made pursuant to an existing Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan that exists as of the date of this prospectus supplement; and (xii)&nbsp;the conversion of ordinary shares into
ADSs or ADSs into ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities
Act. The ADSs, representing our ordinary shares, are listed on The Nasdaq Global Select Market under the symbol &#147;ASND&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this
offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling ADSs in the open market for the purpose of preventing or retarding a decline in the market price of the ADSs while this
offering is in progress. These stabilizing transactions may include making short sales of the ADSs, which involves the sale by the underwriters of a greater number of ADSs than they are required to purchase in this offering, and purchasing ADSs on
the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional ADSs referred to above, or may be
&#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional ADSs, in whole or in part, or by purchasing ADSs in the
open market. In making this determination, the underwriters will consider, among other things, the price of the ADSs available for purchase in the open market compared to the price at which the underwriters may purchase ADSs through the option to
purchase additional ADSs. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market that could adversely affect investors who purchase in
this offering. To the extent that the underwriters create a naked short position, they will purchase ADSs in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the ADSs, including the imposition of penalty bids. This means that
if the representatives of the underwriters purchase ADSs in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those ADSs as part of this offering to repay the underwriting
commissions received by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market price of the ADSs or preventing or retarding a
decline in the market price of the ADSs, and, as a result, the price of the ADSs may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The
underwriters may carry out these transactions on The Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with this offering certain of the underwriters (and selling group members) may
engage in passive market making transactions in the ADSs on The Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on The Nasdaq Global Select Market no higher than the
bid prices of independent market makers and making purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage
of the passive market maker&#146;s average daily trading volume in the ADSs during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of the ADSs to be higher than the price that
otherwise would exist in the open market in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition,
from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity
securities or loans, and may do so in the future. On February&nbsp;8, 2019, we entered into a sales agreement with J.P. Morgan Securities LLC and Morgan Stanley&nbsp;&amp; Co. LLC, as sales agents, under which we may offer and sell ADSs having an
aggregate offering price of up to $200,000,000 over a period of time and from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this
prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering
material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that
jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus
supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member
State of the European Economic Area (each, a &#147;Relevant State&#148;), no ADSs have been offered or will be offered pursuant to this prospectus supplement to the public in that Relevant State prior to the publication of a prospectus in relation
to the ADSs which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus
Regulation, except that the ADSs may be offered to the public in that Relevant State at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the ADSs shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the
ADSs in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, and the
expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No ADSs have been offered or will be offered pursuant to this prospectus supplement to the public in the United Kingdom prior to the publication of a
prospectus in relation to the ADSs which has been approved by the Financial Conduct Authority, except that the ADSs may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, or
the FSMA; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the ADSs shall require us or any underwriter to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the ADSs in the United Kingdom means
the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs and the expression &#147;UK Prospectus
Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs may not be publicly offered
in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been
prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the
listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the ADSs or the offering may be publicly distributed or otherwise made publicly
available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the Company, the ADSs have been or
will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of ADSs will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (&#147;FINMA&#148;), and
the offer of ADSs has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA
does not extend to acquirers of ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre (&#147;DIFC&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (&#147;DFSA&#148;). This document
is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in
connection with Exempt Offers. The DFSA has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not approved this prospectus supplement <I>nor the accompanying prospectus, </I>nor taken steps to verify the information set forth herein and has no responsibility for this document. The
securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the
contents of this document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to its use in the DIFC, this document is strictly private and
confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be
offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International
Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, neither this prospectus supplement nor the
accompanying prospectus constitutes a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. Neither this prospectus supplement nor the accompanying
prospectus has been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth)
(the &#147;Corporations Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission
(&#147;ASIC&#148;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors available under section 708 of the Corporations Act (&#147;Exempt Investors&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs may
not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the ADSs may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any
ADSs may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for
the ADSs, you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As any offer of ADSs under this document will be made without disclosure in
Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions
in section 708 applies to that resale. By applying for the ADSs you undertake to us that you will not, for a period of 12&nbsp;months from the date of issue of the ADSs, offer, transfer, assign or otherwise alienate those ADSs to investors in
Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs have not been and will not be
registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the ADSs nor any interest therein may be offered or sold, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other
entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs have not been offered or sold
and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong
Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of Hong Kong) (the
&#147;CO&#148;) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the ADSs has been or may be issued or has been or may be in the possession of any person for the
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with
respect to ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Singapore SFA Product
Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of ADSs, the Company has determined, and hereby notifies all relevant persons (as defined in
Section&nbsp;309A(1) of the SFA), that the ADSs are prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT>
Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each representative has acknowledged that neither this prospectus supplement nor the accompanying prospectus has been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, each representative has represented and agreed that it has not offered or sold any ADSs or caused the ADSs to be made the subject of an invitation for subscription or purchase and will not offer or sell
any ADSs or cause the ADSs to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement, the accompanying prospectus or any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of
Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA,
or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the ADSs are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
ADSs pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bermuda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADSs may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of
securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable
Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Saudi Arabia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (&#147;CMA&#148;) pursuant to
resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the &#147;CMA Regulations&#148;). The CMA does not make any representation as to the accuracy or completeness of this document and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information
relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>British
Virgin Islands </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or
subscription by or on behalf of the Company. The ADSs may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (&#147;BVI Companies&#148;), but only where the offer will be made to, and received
by, the relevant BVI Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus supplement nor the accompanying prospectus will be circulated or distributed in the PRC and the ADSs will not be offered or sold, and
will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus
supplement, the accompanying prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations
thereunder (the &#147;FSCMA&#148;), and the ADSs have been and will be offered in Korea as a private placement under the FSCMA. None of the ADSs may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder (the &#147;FETL&#148;). The ADSs have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the ADSs
shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the ADSs. By the purchase of the ADSs, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the ADSs pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Malaysia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No prospectus or other offering material or document in connection with the offer and sale of the ADSs has been or will be registered with the
Securities Commission of Malaysia (&#147;Commission&#148;) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, this prospectus supplement, the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation
for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other
than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the ADSs, as principal, if the offer is on terms that the ADSs may only be acquired at a
consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its
equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000&nbsp;(or its equivalent in foreign currencies) per annum in the preceding
twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets
exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee
or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be
specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the ADSs is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The
distribution in Malaysia of this prospectus supplement and the accompanying prospectus is subject to Malaysian laws. Neither this prospectus supplement nor the accompanying prospectus constitutes, nor may they be used for the purpose of public
offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act&nbsp;2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taiwan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs have not been and will not be
registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within
the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise
intermediate the offering and sale of the ADSs in Taiwan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>South Africa </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is defined in the South African
Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the &#147;South African Companies Act&#148;)) is being made in connection with the issue of the ADSs in South Africa. Accordingly, neither this
prospectus supplement nor the accompanying prospectus, nor is either intended to, constitutes a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies
Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The ADSs are not offered, and the offer shall not be transferred, sold,
renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96(1) applies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;96&nbsp;(1)&nbsp;(a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the offer, transfer, sale, renunciation or delivery is to:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal
or agent;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;the South African
Public Investment Corporation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;persons or entities regulated by the Reserve Bank of South Africa;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iv)&#8194;authorised financial service providers
under South African law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(v)&#8194;&#8201;&#8202;financial institutions recognised as such under South African law;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(vi)&#8194;a wholly-owned subsidiary of any
person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law);
or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(vii)&#8201;any combination of the person
in (i)&nbsp;to (vi); or</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;96&nbsp;(1)&nbsp;(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of
South Africa pursuant to section 96(2)(a) of the South African Companies Act.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information made available in this prospectus supplement and the accompanying prospectus should not be considered as
&#147;advice&#148; as defined in the South African Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No South African residents or offshore
subsidiary of a South African resident may subscribe for or purchase any of the ADSs or beneficially own or hold any of the ADSs unless specific approval has been obtained from the financial surveillance department of the South African Reserve Bank
(the &#147;SARB&#148;) by such persons or such subscription, purchase or beneficial holding or ownership is otherwise permitted under the South African Exchange Control Regulations or the rulings promulgated thereunder (including, without
limitation, the rulings issued by the SARB providing for foreign investment allowances applicable to persons who are residents of South Africa under the applicable exchange control laws of South Africa). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are
permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ADSs must be made in accordance with an exemption from,
or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus supplement or the accompanying prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the
time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of
these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_15"></A>EXCHANGE CONTROLS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no laws or regulations in Denmark that restrict the export or import of capital (except for certain investments in certain domains in accordance
with applicable resolutions adopted by the United Nations or the European Union), including, but not limited to, foreign exchange controls, or which affect the remittance of dividends, interest or other payments to
<FONT STYLE="white-space:nowrap">non-resident</FONT> holders of our ordinary shares. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_16"></A>VALIDITY OF THE
SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the shares offered in this prospectus supplement and certain other matters of Danish law will be passed
upon for us by Mazanti-Andersen, Advokatpartnerselskab, Copenhagen, Denmark. Certain matters of U.S. law will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, Menlo Park, California. Cooley&nbsp;LLP, San Francisco, California, and Kromann
Reumert, Copenhagen, Denmark, are acting as counsel for the underwriters in connection with this offering with respect to matters of U.S. law and Danish law, respectively. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_17"></A>MATERIAL CHANGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described above or otherwise described in our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended
December&nbsp;31, 2020 and in our Form <FONT STYLE="white-space:nowrap">6-Ks</FONT> incorporated by reference into this prospectus supplement, no reportable material changes have occurred since December&nbsp;31, 2020. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this Prospectus Supplement by reference from the Company&#146;s Annual Report on Form 20-F for the year ended
December 31, 2020, and the effectiveness of Ascendis Pharma A/S&#146;s internal control over financial reporting have been audited by Deloitte Statsautoriseret Revisionspartnerselskab, an independent registered public accounting firm, as stated in
their reports, which are incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_19"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ascendis Pharma A/S, as well as its subsidiaries Ascendis Pharma, Ophthalmology Division A/S, Ascendis Pharma, Endocrinology Division A/S, Ascendis Pharma
Bone Diseases A/S, Ascendis Pharma Growth Disorders A/S, and Ascendis Pharma Oncology Division A/S are organized under the laws of Denmark, its wholly owned subsidiary Ascendis Pharma GmbH is incorporated under the laws of Germany, and its wholly
owned subsidiaries Ascendis Pharma, Inc. and Ascendis Pharma Endocrinology, Inc. were formed under the laws of the State of Delaware, United States. Substantially all of our assets are located outside the United States. On a combined basis, the
majority of our directors and officers reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in U.S. courts,
including judgments predicated upon the civil liability provisions of the federal securities laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States does not have a
treaty with Denmark or Germany providing for reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Accordingly, a final judgment for the payment of money rendered by a United States
court based on civil liability may not be directly enforceable in Denmark or Germany. However, if the party in whose favor such final judgment is rendered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
brings a new lawsuit in a competent court in Denmark, that party may submit to the Danish court the final judgment that has been rendered in the United States. A judgment by a federal or state
court in the United States will neither be recognized nor enforced by a Danish court but such judgment may serve as evidence in a Danish court. In addition, the final judgment of a United States court may be recognized and enforced in Germany in
compliance with certain requirements including petitioning a German court to enforce such judgment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the periodic
reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we file annual reports and other information with the SEC. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange
Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC maintains a web site that contains reports and information statements and other information about issuers, such as us, who file electronically with
the SEC. The address of that website is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our web site address is <I>www.ascendispharma.com</I>. The information on our web site,
however, is not, and should not be deemed to be, a part of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are
part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Statements in this prospectus
supplement and the accompanying prospectus about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description
of the relevant matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by reference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus supplement and accompanying prospectus, which means that
we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement and accompanying prospectus, and subsequent
information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this
prospectus supplement to the extent that a statement contained in this prospectus supplement modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus
supplement incorporates by reference the documents set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521076349/d123790d20f.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;10, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each Report of Foreign Private Issuer on Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed with the
Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521005711/d46233d6k.htm">January&nbsp;11, 2021</A>&nbsp;(at 06:09:51),&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521008140/d51172d6k.htm">January&nbsp;13, 2021</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521036687/d118120d6k.htm">February 11, 2021</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521075055/d152309d6k.htm">March&nbsp;9, 2021</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521104138/d91747d6k.htm">April&nbsp;1, 2021</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521116783/d171321d6k.htm">April&nbsp;15, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521156654/d102591d6k.htm">May&nbsp;11, 2021</A>&nbsp;(at
06:01:54),&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521159143/d709576d6k.htm">May&nbsp;12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521159552/d492202d6k.htm">May&nbsp;13, 2021</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521177211/d132192d6k.htm">May&nbsp;28, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521187774/d573132d6k.htm">June&nbsp;
10, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521189046/d43343d6k.htm">June&nbsp;14, 2021</A> (accepted June&nbsp;
11, 2021 at 17:31:29), <A HREF="http://www.sec.gov/Archives/edgar/data/1612042/000119312521189585/d148109d6k.htm">June&nbsp;
14, 2021</A> (at 09:00:29), <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521206270/d168596d6k.htm">July&nbsp;1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521208166/d157370d6k.htm">July&nbsp;
6, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521216346/d15474d6k.htm">July&nbsp;15, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521244650/d175955d6k.htm">August&nbsp;
12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1612042/000119312521256645/d175853d6k.htm">August&nbsp;26, 2021</A> (accepted August&nbsp;
25, 2021 at 21:49:00) and <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521257913/d206395d6k.htm">August&nbsp;27, 2021</A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information contained in Exhibits 99.1 and 99.2 to the Report of Foreign Private Issuer on each Report of
Foreign Private Issuer on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521175492/d167568d6k.htm">Form <FONT STYLE="white-space:nowrap">6-K</FONT></A> filed with the SEC on May&nbsp;27, 2021 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our ordinary shares and American Depositary Shares contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1612042/000119312515019449/d855781d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815),</FONT> filed with the SEC under Section&nbsp;12(b) of the Exchange Act, on January&nbsp;26, 2015, including any amendments or reports filed
with the SEC for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also incorporating by reference all subsequent annual reports on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> that we file with the SEC and certain reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that we furnish to the SEC after the date of this prospectus supplement (if such reports on Form <FONT
STYLE="white-space:nowrap">6-K</FONT> expressly state that they are incorporated by reference into the registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-256571))</FONT> prior to the termination of this offering. In all cases, you should rely on the later information over different information included in this prospectus supplement and the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless expressly incorporated by reference, nothing in this prospectus supplement shall be deemed to incorporate by reference information
furnished to, but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus supplement, other than exhibits to those documents unless such exhibits are specially incorporated by reference in this prospectus
supplement, will be provided at no cost to each person, including any beneficial owner, who receives a copy of this prospectus supplement on the written or oral request of that person made to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ascendis Pharma A/S </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tuborg
Boulevard 12 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">DK-2900</FONT> Hellerup, Denmark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+45 70 22 22 44 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_21"></A>EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses, other than any underwriting commissions or agency fees and other items constituting underwriters&#146; or
agents&#146; compensation, expected to be incurred by us in connection with a possible offering of securities registered under the registration statement of which this prospectus supplement is a part. All amounts are estimated other than the SEC
registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158006_22"></A>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT
LIABILITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons
controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158006g81r14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>(or American Depositary Shares representing Ordinary Shares) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preference Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the
securities identified above, and the selling securityholders may offer and sell our ordinary shares (or ADSs representing such shares), in each case from time to time in one or more offerings. This prospectus provides you with a general description
of the securities. We will not receive any proceeds from the sale of our ordinary shares (or ADSs representing such shares) by the selling securityholders (if any). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we or any of the selling securityholders offer and sell securities, we or such selling securityholders will provide a supplement to this prospectus
that contains specific information about the offering and, if applicable, the selling securityholders, as well as the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus
with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement, together with the documents we incorporate by reference, before you invest in any of our securities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or
directly to purchasers, or through a combination of these methods. In addition, the selling securityholders may offer and sell our ordinary shares (or ADSs representing such shares) from time to time, together or separately. If any underwriters,
dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set
forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#147;About this Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus
and the applicable prospectus supplement describing the method and terms of the offering of such securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs, representing our ordinary shares,
are traded on the Nasdaq Global Select Market under the symbol &#147;ASND&#148;. On May&nbsp;26,&nbsp;2021, the last reported sale price for the ADSs on the Nasdaq Global Select Market was $133.77&nbsp;per ADS. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#tx158006_2">RISK FACTORS</A>&#148; ON PAGE&nbsp;3 OF THIS PROSPECTUS AND ANY SIMILAR
SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission, any U.S. state securities commission, the Danish Financial Supervisory Authority, nor any other foreign securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is May&nbsp;27, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_1">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_3">PRINCIPAL MARKETS FOR OUR ORDINARY SHARES AND THE ADSs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_5">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_6">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_8">DESCRIPTION OF OTHER SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_9">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_10">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_11">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_13">EXCHANGE CONTROLS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_15">MATERIAL CHANGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_17">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_18">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx158006_19">EXPENSES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, as a &#147;well-known seasoned
issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended, using a &#147;shelf&#148; registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings and
the selling securityholders to be named in a supplement to this prospectus may, from time to time, sell our ordinary shares (or ADSs representing such shares) from time to time in one or more offerings as described in this prospectus. Each time that
we or the selling securityholders offer and sell such securities, we or the selling securityholders will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the
specific terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add,
update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on
the prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together
with the additional information described under the heading &#147;Where You Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we, nor
the selling securityholders, have authorized any other person to provide you with different or additional information or to make any representations other than those contained in or incorporated by reference into this prospectus, any applicable
prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the selling securityholders take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We and the selling securityholders will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free
writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects
may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are based on
independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information.
In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and other risks and
uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and
under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Ascendis,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean Ascendis Pharma
A/S and its consolidated subsidiaries, unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of the applicable series of securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRESENTATION OF FINANCIAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
maintain our books and records in euros and report under International Financial Reporting Standards, as issued by the International Accounting Standards Board and as adopted by the European Union. None of the consolidated financial statements
incorporated by reference in this prospectus were prepared in accordance with generally accepted accounting principles in the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_1"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are applying our innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company and develop a pipeline of product
candidates with potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> profiles to address unmet medical needs. We have created a portfolio of potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> rare disease endocrinology product candidates to address unmet medical needs by utilizing our TransCon technologies with clinically validated parent drugs. We currently have three product
candidates in clinical development in rare endocrine diseases and two product candidates identified in oncology, our second therapeutic area of focus. We are also working to apply our TransCon technologies in additional therapeutic areas to address
unmet patient needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were organized under the laws of the Kingdom of Denmark in September 2006 as a private limited liability company (Anpartsselskab,
or ApS) and then transformed into a public limited liability company (Aktieselskab, or A/S), effective December&nbsp;17, 2007. In connection with this conversion, our legal name changed from Ascendis Pharma ApS to Ascendis Pharma A/S. We commenced
operations in December 2007 in connection with the acquisition of the company that invented our TransCon technologies, Complex Biosystems GmbH. Our registered office and principal executive offices are located at Tuborg Boulevard 12, <FONT
STYLE="white-space:nowrap">DK-2900</FONT> Hellerup, Denmark and our telephone number is +45 70 22 22 44. Our website address is www.ascendispharma.com. The information on, or that can be accessed through, our website is not, and should not be deemed
to be, part of this prospectus. We have included our website address as an inactive textual reference only. References in this prospectus to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company&#148; or
&#147;Ascendis&#148; refer to Ascendis Pharma A/S, and our consolidated subsidiaries unless otherwise specified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the
risk factors incorporated by reference from our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and any subsequent Annual Reports on Form <FONT STYLE="white-space:nowrap">20-F</FONT> we file after the date of this
prospectus; our updates, if any, to those risk factors in our reports on Form <FONT STYLE="white-space:nowrap">6-K;</FONT> and all other information contained or incorporated by reference into this prospectus or the registration statement of which
this prospectus forms a part, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any
applicable free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_3"></A>PRINCIPAL MARKETS FOR OUR ORDINARY SHARES AND THE ADSs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#147;ASND&#148; since January&nbsp;28, 2015. Prior to this date,
there was no public trading market for our ordinary shares or ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. We will not receive any of the
proceeds from the sale of ordinary shares (or ADSs representing such shares) being offered by any of the selling securityholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_5"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of
association, the registration rights agreement entered into in December&nbsp;2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Agreement, and relevant provisions
of the Danish Companies Act (in Danish: Selskabsloven). Because the following is only a summary, it does not contain all of the information that may be important to you. The summary includes certain references to and descriptions of material
provisions of our articles of association, the 2015 Registration Rights Agreement and Danish law in effect as of the date of this prospectus. The summary below does not purport to be complete and is qualified in its entirety by reference to
applicable Danish Law and our articles of association and the 2015 Registration Rights Agreement, copies of which are incorporated by reference into this prospectus. Further, please note that ADS holders are not treated as our shareholders and do
not have rights as a shareholder. For more information regarding the rights of ADS holders, see &#147;Description of American Depositary Shares&#148; below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company was incorporated on
September&nbsp;21, 2006 as a private limited liability company (in Danish: <I>Anpartsselskab, or ApS</I>) under Danish law and is registered with the Danish Business Authority (in Danish: <I>Erhvervsstyrelsen</I>) in Copenhagen, Denmark under
registration number 29918791. On December&nbsp;17, 2007, our company was converted into a public limited liability company (in Danish: Aktieselskab, or A/S). Our company&#146;s headquarters and registered office is Tuborg Boulevard 12, <FONT
STYLE="white-space:nowrap">DK-2900</FONT> Hellerup, Denmark. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorizations to our board of directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our board of directors is authorized to increase the share capital as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our board of directors is authorized to increase our share capital by up to 4,140,846 shares without <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing shareholders in connection with cash contributions, debt conversion and contributions in kind, provided, however, that the capital increases are carried out at market
value. This authorization is valid until May&nbsp;28, 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our board of directors is authorized to increase our share capital by up to 9,000,000 shares with <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing shareholders in connection with cash contributions. This authorization is valid until May&nbsp;28, 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our board of directors is authorized to issue 618,409 warrants and to increase our share capital by up to nominal
618,409 shares without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof. This authorization
is valid until May&nbsp;28, 2025. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our board of directors is, without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights for the existing
shareholders, authorized to obtain loans against issuance of convertible notes which confer the right to subscribe up to 9,000,000 shares. The convertible notes shall be offered at a subscription price and a conversion price that correspond in
aggregate to at least the market price of the shares at the time of the decision of our board of directors to issue the convertible notes. The loans shall be paid in cash and our board of directors shall determine the terms and conditions for the
convertible notes. This authorization is valid until May&nbsp;28, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our board of directors exercises its authorizations in full,
and all warrants and convertible debt instruments are exercised fully (not including already issued warrants), then our share capital will amount to 76,588,634 shares consisting of 76,588,634 shares with a nominal value of DKK 1 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to hold our Annual General Meeting (the &#147;AGM&#148;) on May&nbsp;28, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the AGM, we have proposed an amendment to our Articles of Association, whereby our board of directors
will be authorized to increase our share capital by up to 9,000,000 shares without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing shareholders in connection with cash contributions, debt conversion and
contributions in kind, provided, however, that the capital increases are carried out at market price. This authorization will be valid until May&nbsp;27, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our AGM, we have proposed an amendment to our Articles of Association, whereby our board of directors will be authorized to issue 2,000,000 warrants and to
increase our share capital by up to 2,000,000 without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and
conditions thereof. This authorization is valid until May&nbsp;27, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Global Select Market under the symbol
&#147;ASND.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our employees,
consultants, advisors and board members are eligible to participate in our warrant incentive program. Warrants have been issued by the general meeting or by our board of directors pursuant to valid authorizations in our articles of association and
the terms and conditions have, in accordance with the Danish Companies Act, been incorporated in our articles of association as in effect from time to time. Each warrant grants the holder the right to subscribe for one ordinary share against cash
payment of the exercise price. The exercise price is determined by our board of directors and historically has not been less than the estimated fair value of our ordinary shares on the date of grant. As of March&nbsp;31, 2021, our board of directors
is authorized to issue 682,509 warrants in the period ending May&nbsp;28, 2025. As of March 31, 2021, there were outstanding 6,109,942 warrants to subscribe for our ordinary shares and such warrants had a weighted average exercise price of
&#128;71.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant of warrants to any participant is at the discretion of our board of directors and based on the recommendation of our management.
The board of directors may determine the terms and conditions of the warrants issued, including exercise periods, subscription price and adjustments caused by changes to our company&#146;s situation. Warrantholders are entitled to an adjustment of
the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes. Events giving rise to an adjustment include, among other things, increases or decreases to our share capital at a price below or above
market value, respectively, the issuance of bonus shares, changes in the nominal value of each share, and payment of dividends in excess of 10% of the Company&#146;s equity. For the purpose of implementing the capital increases necessary in
connection with the exercise of warrants, our board of directors has been authorized to increase our share capital by one or more issuances of shares with a total nominal value corresponding to the number of warrants issued upon cash payment of the
exercise price without any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights to existing shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to earlier vesting
upon the occurrence of certain exit events, warrants granted under the program as in effect since December&nbsp;18, 2015 generally vest 1/48th per month from the date of grant subject to continued service for employees, consultants and initial
grants to board members and 1/24th per month from the date of grant subject to continued service for subsequent grants to board members. Warrants granted under the program as in effect between December&nbsp;2012 and December&nbsp;18, 2015 generally
vest 1/48th per month from the date of grant subject to continued service (previously 1/36th per month for employees and 1/24th per month from the date of grant for board members). With respect to employees, in the event that a holder resigns due to
our breach of employment terms or we terminate the employment relationship and the holder has not given us good reason to do so, the warrants will continue to vest post-termination in accordance with the same vesting schedule. Otherwise, warrants
will cease vesting upon termination of service with respect to employees, board members and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vested warrants may be exercised during certain
exercise periods each year. For 366,537 outstanding warrants, granted in the period 2012 to 2014, there are two annual exercise periods that continue for 21 days from and including the day after the publication of (i)&nbsp;the annual report
notification&#151;or if such notification is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
published&#151;the annual report and (ii)&nbsp;our interim report <FONT STYLE="white-space:nowrap">(six-month</FONT> report). For these warrants, the last exercise period is 21 days from and
including the day after the publication of our interim report for the first half of 2023. For 50,923 outstanding warrants granted in connection with our preference D financing, there are four annual exercise periods that continue for 21 days
following the day of publication of (i)&nbsp;our interim report (three-month report); (ii) the annual report notification&#151;or if such notification is not published&#151;the annual report; (iii)&nbsp;our interim report (six-month report); and
(iv)&nbsp;our interim report (nine-month report). For these warrants, the last exercise period is 21 days following the publication of our interim report (nine-month report) in 2023. For 5,756,582 outstanding warrants granted on or after
December&nbsp;18, 2015, there are four annual exercise periods; each exercise period begins two full trading days after the publication of the public release of our earnings data of a fiscal quarter and continues until the end of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">second-to-last</FONT></FONT> trading day in which quarter the relevant earnings release is published. The warrants granted on or after December&nbsp;18, 2015 expire ten years after the
grant date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2015
Registration Rights Agreement, we were required to timely register with the SEC 1.0&nbsp;million ordinary shares underlying 1.0&nbsp;million ADSs (the &#147;Fidelity Shares&#148;), purchased by Fidelity Securities Fund: Fidelity Series Small Cap
Opportunities Fund&#151;Healthcare Sub and Fidelity Stock Selector Small Cap Fund&#151;Health Care Sub on December&nbsp;14, 2015. In addition, the owners of the Fidelity Shares are entitled to registration of the Fidelity Shares on Form <FONT
STYLE="white-space:nowrap">F-3.</FONT> In accordance with our obligations under the 2015 Registration Rights Agreement, we filed a resale registration statement in February&nbsp;2016 to register for resale the Fidelity Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless our ordinary shares are listed on a national securities exchange or trading system and a market for our ordinary shares not held in the form of ADSs
exists, any registrable securities sold pursuant to an exercise of the registration rights will be sold in the form of ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of
registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2015 Registration Rights Agreement, we agreed to pay certain registration expenses of the holders of the shares registered
pursuant to the registration rights described above, excluding, among other things, the expenses of counsel for Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund&#151;Healthcare Sub and Fidelity Stock Selector Small Cap
Fund&#151;Health Care Sub. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of registration rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2015 Registration Rights Agreement, the registration rights described above will expire upon the earlier of a change of control event, the
disposition of the Fidelity Shares or when the Fidelity Shares can be sold under Rule 144 or Regulation S of the Securities Act during any three-month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Owners&#146; register </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to maintain an
owners&#146; register (in Danish: <I>ejerbog</I>). The owners&#146; register is maintained by Computershare A/S (Company Registration (CVR) no. 27088899), our Danish share registrar. It is mandatory that the owners&#146; register is maintained
within the European Union and that it is available to public authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Danish Companies Act, public and private limited liability
companies are required to register with the Danish Business Authority information regarding shareholders who own at least 5% of the share capital or the voting rights. Pursuant to this provision, we file registrations with the Public Owners&#146;
Register of the Danish Business Authority. Shareholders that exceed the ownership threshold must notify us and we will subsequently file the information with the Danish Business Authority. Reporting is further required when thresholds of 5%, 10%,
15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no longer reached. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of association and Danish corporate law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to our articles of association, the following should be emphasized: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Objects clause </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate object, as set out
in article 3 of our articles of association, is to develop ideas and preparations for the combating of disease medically, to manufacture and sell such preparations or ideas, to own shares of companies with the same objects and to perform activities
in natural connection with these objects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of provisions regarding the board of directors and the executive board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association, our board of directors shall be elected by our shareholders at the general meeting and shall be composed of not less
than three and no more than 10 members. With respect to the duration of the term which our board members severally hold office, the board of directors is classified into two classes as nearly equal in number as possible. Such classes consist of one
class of directors (&#147;Class&nbsp;I&#148;) who were elected at the annual general meeting held in 2019 for a term expiring at the annual general meeting to be held in 2021; and a second class of directors (&#147;Class&nbsp;II&#148;) who were
elected at the annual general meeting held in 2020 for a term expiring at the annual general meeting to be held in 2022. The shareholders shall increase or decrease the number of directors, in order to ensure that the two classes shall be as nearly
equal in number as possible; provided, however, that no decrease shall have the effect of shortening the term of any other director. At each annual general meeting, the successors of the class of directors whose term expires at that meeting shall be
elected to hold office for a term expiring at the annual general meeting held in the second year following the year of their election. Board members must retire from the board of directors at the annual general meeting following their 75th birthday.
Board members are not required to own any shares of our share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors shall appoint and employ an executive board consisting of
one to five members to attend to our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management, and the board of directors shall determine the terms and conditions of the employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each shareholder is entitled to one
vote for each share owned at the time of any general meeting. As compared with Danish citizens, there are no limitations under the articles of association or under Danish law on the rights of foreigners or
<FONT STYLE="white-space:nowrap">non-Danish</FONT> citizens to hold or vote our shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders may at general meetings authorize the distribution of ordinary and extraordinary dividends. Our shareholders may not distribute dividends in
excess of the recommendation from our board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss
carried forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders are eligible to receive any dividends declared and paid out. However, we have not to date declared or paid any
dividends and we currently intend to retain all available financial resources and any earnings generated by our operations for use in the business and we do not anticipate paying any dividends in the foreseeable future. The payment of any dividends
in the future will depend on a number of factors, including our future earnings, capital requirements, financial condition and future prospects, applicable restrictions on the payment of dividends under Danish law and other factors that our board of
directors may consider relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section&nbsp;titled &#147;<I>Item 10 E. Additional Information&#151;Taxation</I>&#148; in our Annual Report on
Form <FONT STYLE="white-space:nowrap">20-F</FONT> for a summary of certain tax consequences in respect of dividends or distributions to holders of our ordinary shares or the ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> subscription rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Danish law, all shareholders have <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights in connection with capital increases that are
carried out as cash contributions. An increase in share capital can be resolved by the shareholders at a general meeting or by the board of directors pursuant to an authorization given by the shareholders. In connection with an increase of a
company&#146;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights of the shareholders. Under the Danish Companies Act, such
resolution must be adopted by the affirmative vote of shareholders holding at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes cast and the share capital represented at the general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may resolve to increase our share capital without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing
shareholders pursuant to the authorizations set forth above under the caption &#147;Authorizations to Our Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless future
issuances of new shares and/or <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be
unable to exercise their <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights on liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of our company, shareholders will be entitled to participate, in proportion to their
respective shareholdings, in any surplus assets remaining after payment of our creditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on holding of shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no limitations on the right to hold shares under the articles of association or Danish law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability to capital calls by us </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our
articles of association as well as the Danish Companies Act, our shareholders are not obligated to pay further amounts to us. All our shares are fully-paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sinking fund provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no sinking fund
provisions or similar obligations relating to our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;55 of the Danish Companies Act, a shareholder is required to notify us when such shareholder&#146;s stake represents 5% or more of the
voting rights in our company or the nominal value accounts for 5% or more of the share capital, and when a change of a holding already notified entails that the limits of 5%, 10%, 15%, 20%, 25%, 50%, 90% or 100%, or 1/3 or 2/3 are reached or no
longer reached. The notification shall be given within two weeks following the date when the limits are reached or are no longer reached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
notification must include information on the date of acquisition or disposal of the shares, the number and, if applicable, the share class, the full name, address and civil registration (CPR) number of the shareholder or the name, central business
register (CVR) number and registered office of the enterprise. If the shareholder has no civil registration (CPR) number or central business (CVR) number, such notice must be accompanied by other documentation securing unambiguous identification of
the shareholder. The notice must also include information on the denomination or nominal value of the shares and the voting rights attaching to the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 58a, we are obligated to collect and store for a period of at least five years certain information regarding the beneficial owners of
shares in the Company. A beneficial owner is a physical person who ultimately holds or controls, directly or indirectly, a sufficient part of the ownership interests or voting rights or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercises control by other means, except for owners of companies whose ownership interests are traded on a regulated market or a similar market which is subject to a duty of disclosure in
accordance with EU law or similar international standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal status of the notification obligations is not fully clarified in relation to ADS
holders and an ADS holder may be subject to such obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders is the highest authority in all matters, subject to the limitations provided by Danish law and the articles of association.
The annual general meeting shall be held in the Greater Copenhagen area not later than the end of May in each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the annual general meeting, the
audited annual report is submitted for approval, together with the proposed appropriations of profit/treatment of loss, the election of the board of directors and election of our auditors. In addition, the board of directors reports on our
activities during the past year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General meetings are convened by the board of directors with a minimum of two weeks&#146; notice and a maximum of four
weeks&#146; notice by letter, fax or by <FONT STYLE="white-space:nowrap">e-mail.</FONT> A convening notice will also be forwarded to shareholders recorded in our owners&#146; register, who have requested such notification and by publication in the
Danish Business Authority&#146;s computerized information system and on the company&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the latest, two weeks before a general meeting
(inclusive of the day of the general meeting), we shall make the following information and documents available on our webpage: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convening notice, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the documents that shall be presented at the general meeting, which will, in the case of the annual general
meeting, include the annual report, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the agenda and the complete proposals. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders are entitled to attend general meetings, either in person or by proxy, and they or their proxy may be accompanied by one advisor. A
shareholder&#146;s right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder holds on the registration date. The registration date shall be one week before the general meeting is
held. The shares which the individual shareholder holds are calculated on the registration date on the basis of the registration of ownership in the owners&#146; register as well as notifications concerning ownership which the Company has received
with a view to update the ownership in the owners&#146; register. In addition, any shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from us no later than three days in advance of
the general meeting. Any shareholder is entitled to submit proposals to be discussed at the general meetings. However, proposals by the shareholders to be considered at the annual general meeting must be submitted in writing to the board of
directors not later than six weeks before the annual general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extraordinary general meetings must be held upon resolution of an annual general
meeting to hold such a meeting or upon request of the board of directors, our auditors or shareholders representing at least 1/20 of the registered share capital or such lower percentage as our articles of association may provide. Our articles of
association do not state such lower percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of ADSs are not entitled to directly receive notices or other materials or to attend or vote at
general meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Resolutions in general meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resolutions made by the general meeting generally may be adopted by a simple majority of the votes cast, subject only to the mandatory provisions of the Danish
Companies Act and our articles of association. Resolutions concerning all amendments to the articles of association must be passed by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast as well as
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#146;s ownership or voting rights, are subject to approval by a nine-tenth majority of the
votes cast and the share capital represented at the general meeting. Decisions to impose or increase any obligations of the shareholders towards the company require unanimity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no quorum
requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and
that such quorum may not be less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Squeeze out </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to Section&nbsp;70 of the Danish Companies Act, shares in a company may be redeemed in full or in part by a shareholder holding more than nine-tenths
of the shares and the corresponding voting rights in the company. Furthermore, according to Section&nbsp;73 of the Danish Companies Act, a minority shareholder may require a majority shareholder holding more than nine-tenths of the shares and the
corresponding voting rights to redeem the minority shareholder&#146;s shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Danish rules intended to prevent market abuse </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;3, 2016, EU Regulation No 596/2014 on market abuse entered into force and Chapter 10 of the Danish Securities Trading Act was repealed.
Pursuant to said Chapter 10, we had adopted an internal code on inside information in respect of the holding of and carrying out of transactions by our board of directors and executive officers and employees in the shares or ADSs or in financial
instruments the value of which is determined by the value of the ordinary shares or ADSs, and we had drawn up a list of those persons working for us who could have access to inside information on a regular or incidental basis and had informed such
persons of the rules on insider trading and market manipulation, including the sanctions which could be imposed in the event of a violation of those rules. However, said EU Regulation No 596/2014 on market abuse imposes no such requirements on us
and we have therefore taken steps to abandon our previous practice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Danish law, members of the board of directors or senior management may be held liable for damages in the event that loss is caused due to their
negligence. They may be held jointly and severally liable for damages to the company and to third parties for acting in violation of the articles of association and Danish law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the Danish Companies Act, the general meeting is allowed to discharge our board members and members of our senior management from liability for
any particular financial year based on a resolution relating to the financial statements. This discharge means that the general meeting will discharge such board members and members of our senior management from liability to us; however, the general
meeting cannot discharge any claims by individual shareholders or other third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we intend to enter, or have entered, into agreements
with our board members and members of our senior management, pursuant to which, subject to limited exceptions, we will agree, or have agreed, to indemnify such board members and members of senior management from civil liability, including
(i)&nbsp;any damages or fines </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable by them as a result of an act or failure to act in the exercise of their duties currently or previously performed by them; (ii)&nbsp;any reasonable costs of conducting a defense against a
claim; and (iii)&nbsp;any reasonable costs of appearing in other legal proceedings in which such individuals are involved as current or former board members or members of senior management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a risk that such agreement will be deemed void under Danish law, either because the agreement is deemed contrary to the rules on discharge of
liability in the Danish Companies Act, as set forth above, because the agreement is deemed contrary to sections&nbsp;19 and 23 of the Danish Act on Damages, which contain mandatory provisions on recourse claims between an employee (including members
of our senior management) and us, or because the agreement is deemed contrary to the general provisions of the Danish Contracts Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to such
indemnification, we provide our board members and senior management with directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Danish
corporate law and our articles of association and Delaware corporate law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following comparison between Danish corporate law, which applies to us,
and Delaware corporate law, the law under which many publicly traded companies in the United States are incorporated, discusses additional matters not otherwise described in this prospectus. This summary is subject to Danish law, including the
Danish Companies Act, and Delaware corporate law, including the Delaware General Corporation Law. Further, please note that ADS holders will not be treated as our shareholders and will not have any shareholder rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Duties of board members </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Public
limited liability companies in Denmark are usually subject to a <FONT STYLE="white-space:nowrap">two-tier</FONT> governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management
of the company in question and with an executive board/management being responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. Each board member and member of the executive
board/management is under a fiduciary duty to act in the interest of the company, but shall also take into account the interests of the creditors and the shareholders. Under Danish law, the members of the board of directors and executive management
of a limited liability company are liable for losses caused by negligence whether shareholders, creditors or the company itself suffers such losses. They may also be liable for wrongful information given in the annual financial statements or any
other public announcements from the company. An investor suing for damages is required to prove its claim with regard to negligence, loss, and causation. Danish courts, when assessing negligence, have been reluctant to impose liability unless the
directors and officers neglected clear and specific duties. This is also the case when it comes to liability with regard to public offerings or liability with regard to any other public information issued by the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this
function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business
judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct
upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or <FONT
STYLE="white-space:nowrap">break-up</FONT> of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms of the members of our board of directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, the members of the board of directors of a limited liability company are generally appointed for an individual term of one
year. There is no limit on the number of consecutive terms the board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
members may serve. Pursuant to our articles of association, our board members are appointed by the general meeting of shareholders for a term of two years and are divided into two classes.
Election of board members is, according to our articles of association, an item that shall be included on the agenda for the annual general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
the general meeting, shareholders are entitled at all times to dismiss a board member by a simple majority vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It follows from Section&nbsp;140 of the
Danish Companies Act that in limited liability companies that have employed an average of at least 35 employees in the preceding three years, the employees are entitled to elect a minimum of two representatives and alternate members to the
company&#146;s board of directors up to one half the number of the shareholder elected directors. If the number of representatives to be elected by the employees is not a whole number, such number must be rounded up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company currently employs more than an average of 35 employees and has done so since 2016. Consequently, from 2018, our employees have been entitled to
demand representation on our board of directors. The question will, upon request from the employees, be put to a popular vote among the employees. If more than half of the employees (regardless whether they participate in the vote) vote in favor of
having representation, we must organize an election process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Section&nbsp;141 of the Danish Companies Act allows for group representation
on the board of directors of our Company, <I>i.e. </I>that employees of our Danish subsidiaries may demand representation on our board. However, our Danish subsidiaries do not currently have employees. The employees of Ascendis Pharma, Inc. and
Ascendis Pharma Endocrinology, Inc., and the employees of our other foreign subsidiary, Ascendis Pharma GmbH, may only demand representation on our board of directors provided that our general meeting adopts a resolution to that effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law generally provides for a <FONT STYLE="white-space:nowrap">one-year</FONT> term for directors, but
permits directorships to be divided into up to three classes, of relatively equal size, with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a
bylaw adopted by the stockholders. A director elected to serve a term on a &#147;classified&#148; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board member vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under
Danish law, in the event of a vacancy, new board members are elected by the shareholders in a general meeting. Thus, a general meeting will have to be convened to fill a vacancy on the board of directors. However, the board of directors may choose
to wait to fill vacancies until the next annual general meeting of the company, provided that the remaining board members can still constitute a quorum. It is only a statutory requirement to convene a general meeting to fill vacancies if the number
of remaining members on the board is less than two. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law provides that vacancies and newly created
directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (1)&nbsp;otherwise provided in the certificate of incorporation or bylaws of the corporation or (2)&nbsp;the certificate of
incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Conflict-of-interest</FONT></FONT> transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, board members may not take part in any matter or decision-making that involves a subject or transaction in relation to which
the board member has a conflict of interest with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law generally permits transactions involving a Delaware
corporation and an interested director of that corporation if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts as to the director&#146;s relationship or interest are disclosed and a majority of
disinterested directors&#146; consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts are disclosed as to the director&#146;s relationship or interest and a majority of shares
entitled to vote thereon consent; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of
the board of directors or the stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proxy voting by board members </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. In the event that a board member in a Danish limited liability company is unable to participate in a board meeting, the elected alternate, if
any, shall be given access to participate in the board meeting. Unless the board of directors has decided otherwise, or as otherwise is set out in the articles of association, the board member in question may grant a power of attorney to another
board member, provided that this is considered safe considering the agenda in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. A director of a Delaware corporation may not
issue a proxy representing the director&#146;s voting rights as a director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Notice of meeting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. According to the Danish
Companies Act, general meetings in limited liability companies shall be convened by the board of directors with a minimum of two weeks&#146; notice and a maximum of four weeks&#146; notice as set forth in the articles of association. A convening
notice shall also be forwarded to shareholders recorded in our owners&#146; register, who have requested such notification. There are specific requirements as to the information and documentation required to be disclosed in connection with the
convening notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any
meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Each ordinary share
confers the right to cast one vote at the general meeting of shareholders, unless the articles of association provide otherwise. Each holder of ordinary shares may cast as many votes as it holds shares. Shares that are held by us or our direct or
indirect subsidiaries do not confer the right to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, each stockholder is entitled to one
vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under
specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event can a quorum
consist of less than one third of the shares entitled to vote at a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders as of the record date for the meeting are entitled to vote at
the meeting, and the board of directors may fix a record date that is no more than 60 nor less than ten days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day
on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board
of directors may fix a new record date for the adjourned meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. According to the Danish Companies Act, extraordinary general meetings of shareholders will be held whenever our board of directors or our
appointed auditor requires. In addition, one or more shareholders representing at least 1/20th of the registered share capital of the company may, in writing, require that a general meeting be convened. If such a demand is forwarded, the board of
directors shall convene the general meeting within two weeks thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shareholders have the right to present proposals for adoption at the annual
general meeting, provided that the proposals are forwarded at the latest six weeks prior thereto. In the event that the proposal is received at a later date, the board of directors will decide whether the proposal has been forwarded in due time to
be included on the agenda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Delaware law does not specifically grant stockholders the right to bring business before an annual or special
meeting of stockholders. However, if a Delaware corporation is subject to the SEC&#146;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#146;s securities entitled to vote, may propose a matter for a
vote at an annual or special meeting in accordance with those rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by written consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, it is permissible for shareholders to take action and pass resolutions by written consent in the event of unanimity; however,
this will normally not be the case in listed companies and for a listed company, this method of adopting resolutions is generally not feasible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written
consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appraisal rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. The
concept of appraisal rights does not exist under Danish law, except in connection with statutory redemptions rights according to the Danish Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to Section&nbsp;73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the
company&#146;s registered share capital and votes to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company&#146;s share capital and votes may, according to Section&nbsp;70 of the same act, squeeze out the
minority shareholders. In the event that the parties cannot agree to the redemption squeeze out price, this shall be determined by an independent evaluator appointed by the court. Additionally, there are specific regulations in Sections&nbsp;249,
267, 285 and 305 of the Danish Companies Act that require compensation in the event of national or cross-border mergers and demergers. Moreover, shareholders who vote against a cross-border merger or demerger are, according to Sections&nbsp;286 and
306 of the Danish Companies Act, entitled to have their shares redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law provides for stockholder
appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#146;s shares, in connection with certain mergers and consolidations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder suits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, only a company itself can bring a civil action against a third party; an individual shareholder does not have the right to
bring an action on behalf of a company. An individual shareholder may, in its own name, have an individual right to take action against such third party in the event that the cause for the liability of that third party also constitutes a negligent
act directly against such individual shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, a stockholder may bring a derivative
action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action
under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally
must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to
assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repurchase of
shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark. </I>Danish limited liability companies may not subscribe for newly issued shares in their own capital. Such company may, however,
according to the Danish Companies Act <FONT STYLE="white-space:nowrap">Sections&nbsp;196-201,</FONT> acquire fully paid shares of its own capital, provided that the board of directors has been authorized thereto by the shareholders acting in a
general meeting. Such authorization can only be given for a maximum period of five years and the authorization shall fix (i)&nbsp;the maximum value of the shares and (ii)&nbsp;the minimum and the highest amount that the company may pay for the
shares. Shares may generally only be acquired using distributable reserves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, a corporation
may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital
any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-takeover provisions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish
law, it is possible to implement limited protective anti-takeover measures. Such provisions may include, among other things, (i)&nbsp;different share classes with different voting rights, (ii)&nbsp;specific requirements to register the shares named
in the company&#146;s owners register and (iii)&nbsp;notification requirements concerning participation in general meetings. We have currently not adopted any such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General
Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the Delaware General Corporation Law prohibits &#147;business combinations,&#148; including mergers, sales and leases of
assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#146;s voting stock, within three years after the person becomes an
interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction that will cause the person to become an interested stockholder is approved by the board of
directors of the target prior to the transaction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the completion of the transaction in which the person becomes an interested stockholder, the interested
stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the person becomes an interested stockholder, the business combination is approved by the board of
directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may elect not to be governed by Section&nbsp;203 by a provision contained in the original certificate of incorporation of the
corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the
corporation. Such an amendment is not effective until 12 months following its adoption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Inspection of books and records </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. According to Section&nbsp;150 of the Danish Companies Act, a shareholder may request an inspection of the company&#146;s books regarding
specific issues concerning the management of the company or specific annual reports. If approved by shareholders with simple majority, one or more investigators are elected. If the proposal is not approved by simple majority but 25% of the share
capital votes in favor, then the shareholder can request the court to appoint an investigator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation
Law, any stockholder may inspect certain of the corporation&#146;s books and records, for any proper purpose, during the corporation&#146;s usual hours of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, all shareholders have <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights in connection with capital
increases that are carried out as cash contributions. In connection with an increase of a company&#146;s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT>
majority of the votes cast and the share capital represented at the general meeting. The board of directors may resolve to increase our share capital without <FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights for existing
shareholders pursuant to the authorizations described above under the caption &#147;Authorizations to Our Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless future
issuances of new shares are registered under the Securities Act or with any authority outside Denmark, U.S. shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their
<FONT STYLE="white-space:nowrap">pre-emptive</FONT> subscription rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, stockholders have
no <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of
incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under
Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company&#146;s shareholders at a company&#146;s general meeting. The shareholders may not distribute dividends in excess of the recommendation from the
board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward. It is possible under
Danish law to pay out interim dividends. The decision to pay out interim dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an
interim balance sheet for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period from the annual report period until the interim dividend payment shall be prepared. If interim dividends are paid out later than six months following the financial year for the latest
annual report, an interim balance sheet showing that there are sufficient funds shall always be prepared. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General
Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding
fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In
determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard
to their historical book value. Dividends may be paid in the form of shares, property or cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder vote on certain reorganizations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. Under Danish law, all amendments to the articles of association shall be approved by the general meeting of shareholders with a minimum of <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast and <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the represented share capital. The same applies to solvent liquidations, mergers with the company as the discontinuing entity,
mergers with the company as the continuing entity if shares are issued in connection therewith and demergers. Under Danish law, it is debatable whether the shareholders must approve a decision to sell all or virtually all of the company&#146;s
business/assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled
to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of
incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, unless required by the
certificate of incorporation, if (1)&nbsp;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (2)&nbsp;the shares of stock of the surviving corporation are not changed in the merger
and (3)&nbsp;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#146;s common stock
outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such
corporation, but the stockholders will be entitled to appraisal rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendments to governing documents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Denmark</I>. All resolutions made by the general meeting may be adopted by a simple majority of the votes, subject only to the mandatory provisions of the
Danish Companies Act and the articles of association. Resolutions concerning all amendments to the articles of association must be passed by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast as well as <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder&#146;s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes
cast and the share capital represented at the general meeting. Decisions to impose any or increase any obligations of the shareholders towards the company require unanimity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, a corporation&#146;s certificate of incorporation may be amended only if adopted and declared
advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the
certificate of incorporation, also be amended by the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_6"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary for the ADSs is The Bank of
New York Mellon. The Bank of New York Mellon&#146;s depositary office and its principal executive office are located at 240 Greenwich Street, New York, New York 10286. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>American Depositary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon,
as depositary, registers and delivers the ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with The Bank of New York Mellon, London Branch, or any successor, as custodian for the depositary. Each ADS
also represents any other securities, cash or other property which may be held by the depositary in respect of the depositary facility. The depositary&#146;s corporate trust office at which the ADSs are administered and its principal executive
office is located at 240 Greenwich Street, New York, New York 10286. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may hold ADSs either (1)&nbsp;directly (a)&nbsp;by having an American Depositary
Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (b)&nbsp;by having ADSs registered in your name in the Direct Registration System, or (2)&nbsp;indirectly by holding a
security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs
indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures
are. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Direct Registration System, or DRS, is a system administered by The Depository Trust Company, also referred to as DTC, pursuant to which the
depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by periodic statements sent by the depositary to the registered holders of uncertificated ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADS holders are not treated as shareholders and do not have shareholder rights. Danish law governs shareholder rights. The depositary is the holder of the
ordinary shares underlying the ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and all other persons directly and indirectly holding ADSs sets out ADS holder rights
as well as the rights and obligations of the depositary. A copy of the deposit agreement is incorporated by reference as an exhibit to our Annual Report on form <FONT STYLE="white-space:nowrap">20-F.</FONT> New York law governs the deposit agreement
and the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire
deposit agreement and the form of ADS.&nbsp;For directions on how to obtain copies of those documents, see the section&nbsp;of this prospectus titled &#147;<I>Where You Can Find Additional Information; Incorporation by Reference.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How will you
receive dividends and other distributions on the ordinary shares? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary has agreed to pay you the cash dividends or other distributions
it or the custodian receives on ordinary shares or other deposited securities, after deducting its fees and expenses. As an ADS holder, you will receive these distributions in proportion to the number of ordinary shares your ADSs represent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash</I>. We do not expect to declare or pay any cash dividends or cash distributions on our ordinary shares for the foreseeable future. The depositary
will convert any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary shares, rights, securities or other entitlements into U.S. dollars if it can do so on a reasonable basis and at
the then prevailing market rate, and can transfer the U.S. dollars to the United States. If that is not possible and lawful or if any government approval is needed and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it
cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any taxes or other governmental charges, together with fees
and expenses of the depositary that must be paid, will be deducted. See the section&nbsp;titled &#147;<I>Item 10 E. Additional Information&#151;Taxation</I>&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for a
summary of certain tax consequences in respect of dividends or distributions to holders of ADSs. It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent.&nbsp;If the exchange rates fluctuate
during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares</I>.
The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution to the extent reasonably practicable and permissible under law. The depositary will only distribute whole ADSs. If the
depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new ordinary shares. The depositary may sell a portion of the distributed ordinary shares sufficient to pay its fees and expenses in connection with that
distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elective Distributions in Cash or Shares</I>. If we offer holders of our ordinary shares the option to receive dividends in either cash
or shares, the depositary, after consultation with us, may make such elective distribution available to you as a holder of the ADSs. We must first instruct the depositary to make such elective distribution available to you. As a condition of making
a distribution election available to ADS holders, the depositary may require satisfactory assurances from us that doing so would not require registration of any securities under the Securities Act. There can be no assurance that you will be given
the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights to Purchase
Additional Ordinary Shares</I>. If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may make these rights available to ADS holders. If the depositary decides it is not
legal and practical to make the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and distribute the proceeds in the same way as it does with cash distributions. The
depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the depositary makes rights
available to you, it will exercise the rights and purchase the ordinary shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver ADSs to you. It will only exercise rights if you
pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. securities laws may
restrict transfers and cancellation of the ADSs representing ordinary shares purchased upon exercise of rights. For example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted
depositary shares that have the same terms as the ADSs described in this section&nbsp;except for changes needed to put the necessary restrictions in place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Distributions</I>. The depositary will send to you anything else we distribute to holders of deposited securities by any means it determines is
equitable and practicable. If it cannot make the distribution proportionally among the owners, the depositary may adopt another equitable and practical method. It may decide to sell what we distributed and distribute the net proceeds, in the same
way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However,
the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the
distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the depositary are responsible for any failure to determine that it may be lawful or feasible
to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights or other securities under the Securities Act. This means that you may not receive the distributions we make on our ordinary shares
or any value for them if it is illegal or impractical for us to make them available to you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deposit, Withdrawal and Cancellation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How are ADSs issued? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will deliver
ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, and
delivery of any required endorsements, certifications or other instruments of transfer required by the depositary, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of
the person or persons that made the deposit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can ADS holders withdraw the deposited securities? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may surrender your ADSs at the depositary&#146;s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp
taxes or share transfer taxes or fees, the depositary will transfer and deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person designated by you at the office of the custodian or through a book-entry
delivery. Alternatively, at your request, risk and expense, the depositary will transfer and deliver the deposited securities at its corporate trust office, if feasible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can ADS holders interchange between certificated ADSs and uncertificated ADSs? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated ADSs. The depositary will cancel the ADRs and will
send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for
certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How do you vote? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may instruct the depositary
to vote the number of whole deposited ordinary shares your ADSs represent. The depositary will notify you of shareholders&#146; meetings or other solicitations of consents and arrange to deliver our voting materials to you if we ask it to. Those
materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will try, as far as practical, and subject to the laws of Denmark and our Articles of Association, to vote or to have its agents vote the
ordinary shares or other deposited securities as instructed by ADS holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will only vote or attempt to vote as you instruct or as
described above. If we ask the depositary to solicit the ADS holders&#146; instructions to vote and an ADS holder fails to instruct the depositary as to the manner in which to vote by the specified date, such ADS holder will be deemed to have given
a discretionary proxy to a person designated by us to vote the number of deposited securities represented by its ADSs, unless we notify the depositary that we do not wish to receive a discretionary proxy, there is substantial shareholder opposition
to the particular question, or the particular question would have an adverse impact on our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the
depositary to vote your ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions provided that any such failure is in good
faith. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request
the depositary to act, we will try to give the depositary notice of any such meeting and details concerning the matters to be voted upon sufficiently in advance of the meeting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described above, you will not be able to exercise your right to vote unless you withdraw the ordinary shares. However, you may not know about the
shareholder meeting far enough in advance to withdraw the ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What fees and expenses will you be responsible for paying? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Persons depositing or withdrawing ordinary shares or For: ADSs must pay:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Issue of ADSs, including issues resulting from a distribution of ordinary
shares or rights or other property</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cancellation of ADSs for the purpose of withdrawal, including if the
deposit agreement terminates</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Any cash distribution to you</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$0.05 (or less) per ADS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Distribution of securities distributed to holders of deposited securities
which are distributed by the depositary to you</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Depositary services</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$0.05 (or less) per ADS per calendar year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Transfer and registration of ordinary shares on our share register to or
from the name of the depositary or its agent when you deposit or withdraw shares</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration or transfer fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cable, telex and facsimile transmissions (when expressly provided in the
deposit agreement)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expenses of the depositary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Converting foreign currency to U.S. dollars</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, share transfer taxes, stamp duty or withholding taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;As necessary</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Any charges incurred by the depositary or its agents for servicing the deposited securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;As necessary</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing
ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a
portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide
<FONT STYLE="white-space:nowrap">for-fee</FONT> services until its fees for those services are paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the depositary may make payments
to us to reimburse or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing
its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates of the depositary and that may earn or share fees or commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be responsible for any taxes
or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your
ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited
securities, it will, if appropriate, reduce the number of ADSs registered in your name to reflect the sale and pay you any net proceeds, or send you any property, remaining after it has paid the taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reclassifications, Recapitalizations and Mergers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>If we:</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><I>Then:</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Change the nominal or par value of our ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The cash, ordinary shares or other securities received by the depositary will become deposited securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reclassify, split up or consolidate any of the deposited securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Each ADS will automatically represent its equal share of the new deposited securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribute securities on the ordinary shares that are not distributed to
you</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The depositary may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and distribute
the net proceeds if we are unable to assure the depositary that the distribution (a)&nbsp;does not require registration under the Securities Act or (b)&nbsp;is exempt from registration under the Securities Act.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Recapitalize, reorganize, merge, liquidate, sell all or substantially all of
our assets, or take any similar action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing ADSs or, if necessary, replacement ADSs distributed by the depositary will represent the replacement
securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all ADS holders.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How may the deposit agreement be amended? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for
registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At
the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How may the deposit agreement be terminated? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
depositary will terminate the deposit agreement at our direction by mailing notice of termination to the ADS holders then outstanding at least 30 days prior to the date fixed in such notice for such termination. The depositary may also terminate the
deposit agreement by mailing a notice of termination to us and the ADS holders if 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited
securities, sell rights and other property, and deliver ordinary shares and other deposited securities upon cancellation of ADSs. Four months after termination, the depositary may sell any remaining deposited securities by public or private sale.
After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the
money and has no liability for interest. The depositary&#146;s only obligations will be to account for the money and other cash. After termination our only obligations under the deposit agreement will be to indemnify the depositary and to pay fees
and expenses of the depositary that we agreed to pay and we will not have any obligations thereunder to current or former ADS holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on
Obligations and Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limits on our obligations and the obligations of the depositary; limits on liability to holders of ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary.
We and the depositary: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad
faith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not liable if either of us is prevented or delayed by law or circumstances beyond our control from performing
our </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ligations under the deposit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not liable if either of us exercises, or fails to exercise, discretion permitted under the deposit agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities
that is not made </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or
punitive damages for any breach of the terms of the deposit agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not liable for any tax consequences to any holders of ADSs on account of their ownership of ADSs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit
agreement on your behalf or on behalf of any other person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may rely upon any documents we believe in good faith to be genuine and to have been signed or presented by the
proper person. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. Additionally,
we, the depositary and each owner and holder, to the fullest extent permitted by applicable law, waive the right to a jury trial in an action against us or the depositary arising out of or relating to the deposit agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Requirements for Depositary Actions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the
depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of ordinary shares, the depositary may require: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of share transfer or other taxes or other governmental charges and transfer or registration fees charged
by third parties for the transfer of any ordinary shares or other deposited securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including
presentation of transfer documents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer
books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your Right to Receive the
Ordinary Shares Underlying Your ADSs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">when temporary delays arise because: (1)&nbsp;the depositary has closed its transfer books or we have closed our
transfer books; (2)&nbsp;the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting; or (3)&nbsp;we are paying a dividend on our ordinary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">when you owe money to pay fees, taxes and similar charges; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that
apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This right of withdrawal is not limited by any
other provision of the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-release</FONT> of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement permits the depositary to deliver ADSs before deposit of the underlying ordinary shares. This is called a
<FONT STYLE="white-space:nowrap">pre-release</FONT> of the ADSs. The depositary may also deliver ordinary shares upon cancellation of <FONT STYLE="white-space:nowrap">pre-released</FONT> ADSs (even if the ADSs are canceled before the <FONT
STYLE="white-space:nowrap">pre-release</FONT> transaction has been closed out). A <FONT STYLE="white-space:nowrap">pre-release</FONT> is closed out as soon as the underlying ordinary shares are delivered to the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may receive ADSs instead of ordinary shares to close out a <FONT STYLE="white-space:nowrap">pre-release.</FONT> The depositary may <FONT
STYLE="white-space:nowrap">pre-release</FONT> ADSs only under the following conditions: (1)&nbsp;before or at the time of the <FONT STYLE="white-space:nowrap">pre-release,</FONT> the person to whom the
<FONT STYLE="white-space:nowrap">pre-release</FONT> is being made represents to the depositary in writing that it or its customer owns the ordinary shares or ADSs to be deposited; (2)&nbsp;the <FONT STYLE="white-space:nowrap">pre-release</FONT> is
fully collateralized with cash or other collateral that the depositary considers appropriate; and (3)&nbsp;the depositary must be able to close out the <FONT STYLE="white-space:nowrap">pre-release</FONT> on not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more than five business days&#146; notice. In addition, the depositary will limit the number of ADSs that may be outstanding at any time as a result of prerelease to 30% of the number of
deposited shares, although the depositary may disregard this limit from time to time if it determines it is appropriate to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Direct Registration
System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply
to uncertificated ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated ADSs and such ownership will be evidenced by periodic statements sent by the
depositary to the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs
to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the
depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the
ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#146;s reliance on and compliance with instructions received by the depositary through the DRS/Profile
System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder
Communications; Inspection of Register of Holders of ADSs; ADS Holder Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will make available for your inspection at its office
all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications if we ask it to. You have a right to
inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes
certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have
summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In
the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#147;Ascendis,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; refer to Ascendis Pharma A/S excluding our subsidiaries,
unless expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to
such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one
or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable
prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will
be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#147;Global Securities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus
supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the
debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a
&#147;successor person&#148;) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Ascendis) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction or Denmark and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Event of Default&#148; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Ascendis and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Ascendis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section&nbsp;6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at
the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding
debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in
principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any,
with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular
provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by
it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the
appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that
series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to
the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice
is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its
consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series
may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by
the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the
trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency,
that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or
investment bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the
terms of the indenture and those debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of
counsel stating that we have received from, or there has been published by, the United States Internal Revenue Service, or the IRS, a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States
federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as
a result of the deposit, defeasance and discharge and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not
occurred. (Section 8.3) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable
series of debt securities, upon compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#147;covenant defeasance&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees or Securityholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our obligations under the
debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the
consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities,
including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may
be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by
their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any
process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding
brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_8"></A>DESCRIPTION OF OTHER SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement a description of any preference shares, warrants, units or depositary shares issued by us that may
be offered and sold pursuant to this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_9"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we indicate
differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and certain of the securities may be represented by one or more global notes or global securities, or,
collectively, global securities. Any global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless
and until it is exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary of such global security to its nominee or by
the nominee to the depositary of such global security, or by the depositary or its nominee to a successor depositary of such global security or to a nominee of the successor depositary of such global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates. &#147;Direct
participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp; Clearing
Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries.
Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC
and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through direct participants, which will
receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#146; records.
Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of
their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of
beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#146;s partnership
nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee will not change the
beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may
not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form and represented by one or more global securities, you will
receive payments and may transfer securities only through the facilities of the depositary of the global securities and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement
for the applicable securities represented by one or more global securities, where notices and demands in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment,
registration of transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect
participants and by direct participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption notices with respect to securities represented by one or more global securities will be sent to DTC. If less than all of the securities represented
by one or more global securities of a particular series are being redeemed, DTC&#146;s practice is to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities represented by one or more global
securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of Cede&nbsp;&amp; Co. to those direct participants to whose accounts
the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as securities are in
book-entry form and represented by one or more global securities, we will make payments on those securities to the depositary of the global securities or its nominee, as the registered owner of such securities, by wire transfer of immediately
available funds. If securities represented by one or more global securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities
herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the
applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities represented by one or more global securities will be made to Cede&nbsp;&amp; Co.,
or such other nominee as may be requested by an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date
in accordance with their respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in
bearer form or registered in &#147;street name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds,
distributions and dividend payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and
disbursement of payments to the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances
described below, purchasers of securities represented by one or more global securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner of
securities represented by one or more global securities must rely on the procedures of DTC and its participants to exercise any rights under the securities and the indenture. The laws of some jurisdictions may require that some purchasers of
securities take physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities represented by one or more global securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the securities
represented by one or more global securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered for
securities represented by one or more global securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities represented by one or
more global securities generally will not receive certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities represented by one
or more global securities, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the
global securities. Any beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form or book-entry form registered in the
names that the depositary of such global security directs. It is expected that these directions will be based upon directions received by the depositary of the global securities from its participants with respect to ownership of beneficial interests
in the global securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as
&#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to as &#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are
participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of
their respective U.S. depositaries, which in turn will hold such interests in customers&#146; securities accounts in such depositaries&#146; names on DTC&#146;s books. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and Euroclear hold securities for their respective participating
organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating the need for physical movement of certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in global securities owned through Euroclear or
Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are also subject to DTC&#146;s rules and
procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving
any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cross-market transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand,
will be effected through DTC in accordance with the DTC&#146;s rules on behalf of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as
the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its
settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance
with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream purchasing an interest in a global security from a direct
participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which must be a business day for Euroclear or Clearstream)
immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or Clearstream to a direct participant in DTC will be
received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following DTC&#146;s settlement date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this section of this
prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided
solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has
any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect
that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours
will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_10"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about selling securityholders, where applicable, will be set forth in a prospectus supplement, in a post-effective amendment or in filings we make
with the SEC under the Exchange Act that are incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_11"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Material income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will be set forth in
the applicable prospectus supplement(s) relating to the offering of those securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or any of the selling securityholders may sell the offered securities from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will identify the specific plan of distribution, including any underwriters, dealers, agents or direct purchasers and their compensation in the applicable
prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_13"></A>EXCHANGE CONTROLS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no laws or regulations in Denmark that restrict the export or import of capital (except for certain investments in certain domains in accordance
with applicable resolutions adopted by the United Nations or the European Union), including, but not limited to, foreign exchange controls, or which affect the remittance of dividends, interest or other payments to
<FONT STYLE="white-space:nowrap">non-resident</FONT> holders of our ordinary shares. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_14"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the ordinary shares and preference shares offered in this prospectus and certain other matters of Danish law will be passed
upon for us by Mazanti-Andersen Advokatpartnerselskab, Copenhagen, Denmark. The validity of the debt securities, warrants, units and depositary shares and certain other matters will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, Menlo Park,
California. Additional legal matters may be passed upon for us, the selling securityholders or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_15"></A>MATERIAL CHANGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described above or otherwise described in our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended
December&nbsp;31, 2020 and in our Form <FONT STYLE="white-space:nowrap">6-Ks</FONT> incorporated by reference into this prospectus, no reportable material changes have occurred since December&nbsp;31, 2020. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_16"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial statements incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form 20-F, and the effectiveness of Ascendis Pharma A/S&#146;s internal control over financial reporting have been audited by Deloitte
Statsautoriseret Revisionspartnerselskab, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the reports of
such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_17"></A>ENFORCEMENT OF CIVIL LIABILITIES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ascendis Pharma A/S, as well as its subsidiaries Ascendis Pharma, Endocrinology Division A/S, Ascendis Pharma, Ophthalmology Division A/S, Ascendis
Pharma Bone Diseases A/S, Ascendis Pharma Growth Disorders A/S, Ascendis Pharma Oncology Division A/S, are organized under the laws of Denmark, its wholly owned subsidiary Ascendis Pharma GmbH is incorporated under the laws of Germany, and its
wholly owned subsidiaries Ascendis Pharma, Inc. and Ascendis Pharma Endocrinology, Inc. were formed under the laws of the State of Delaware, United States. Substantially all of our assets are located outside the United States. On a combined basis,
the majority of our directors and officers reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in U.S. courts,
including judgments predicated upon the civil liability provisions of the federal securities laws of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States does not have a treaty with Denmark or Germany providing for reciprocal recognition and
enforcement of judgments, other than arbitration awards, in civil and commercial matters. Accordingly, a final judgment for the payment of money rendered by a United States court based on civil liability may not be directly enforceable in Denmark or
Germany. However, if the party in whose favor such final judgment is rendered brings a new lawsuit in a competent court in Denmark, that party may submit to the Danish court the final judgment that has been rendered in the United States. A judgment
by a federal or state court in the United States will neither be recognized nor enforced by a Danish court but such judgment may serve as evidence in a Danish court. In addition, the final judgment of a United States court may be recognized and
enforced in Germany in compliance with certain requirements including petitioning a German court to enforce such judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_18"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the
periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we file annual reports and other information with the SEC. As a foreign private issuer, we are exempt from, among other things, the rules under the
Exchange Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC maintains a web site that contains reports and information statements and other information about issuers, such as us, who file electronically
with the SEC. The address of that website is http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our web site address is <I>www.ascendispharma.com</I>. The information on our website,
however, is not, and should not be deemed to be, a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration
statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Other documents establishing the terms of the
offered securities are or may be filed as exhibits to the registration statement of which this prospectus forms a part. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in
all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You obtain a copy of the registration statement through the SEC&#146;s website, as
provided above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information
incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by
reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the
SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521076349/d123790d20f.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the year ended December&nbsp;31, 2020, filed by us with the SEC on March&nbsp;10, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished by us with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521005711/d46233d6k.htm">January&nbsp;11,
 2021</A> (at 06:09:51), <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521008140/d51172d6k.htm">January&nbsp;
13, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521036687/d118120d6k.htm">February&nbsp;11, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521075055/d152309d6k.htm">March&nbsp;9,
2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521104138/d91747d6k.htm">April&nbsp;1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521116783/d171321d6k.htm">April&nbsp;
15, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521156654/d102591d6k.htm">May&nbsp;11, 2021</A> (at 06:01:54), <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521159143/d709576d6k.htm">May&nbsp;
12, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521159552/d492202d6k.htm">May&nbsp;13, 2021</A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information contained in Exhibits 99.1 and 99.2 of the Report on <A HREF="http://www.sec.gov/Archives/edgar/data/0001612042/000119312521175492/d167568d6k.htm">Form
 <FONT STYLE="white-space:nowrap">6-K</FONT></A> filed with the SEC on May&nbsp;27, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Ordinary Shares and American Depositary Shares contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1612042/000119312515019449/d855781d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36815),</FONT> filed by us with the SEC under Section&nbsp;12(b) of the Exchange Act, on January&nbsp;26, 2015, including any amendments or reports
filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also incorporating by reference all subsequent annual reports on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> that we file with the SEC and certain reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that we furnish to the SEC after the date of this prospectus (if such reports on Form <FONT
STYLE="white-space:nowrap">6-K</FONT> expressly state that they are incorporated by reference into the registration statement of which this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus forms a part) prior to the termination of this offering. In all cases, you should rely on the later information over different information included in this prospectus or any
accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference
information furnished to, but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specially incorporated by reference in this prospectus, will
be provided at no cost to each person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ascendis Pharma A/S </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tuborg
Boulevard 12 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">DK-2900</FONT> Hellerup, Denmark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+45 70 22 22 44 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx158006_19"></A>EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses, other than any underwriting commissions or agency fees and other items constituting underwriters&#146; or
agents&#146; compensation, expected to be incurred by us in connection with a possible offering of securities registered under the registration statement of which this prospectus is a part. All amounts are expected to be estimated other than the SEC
registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Nasdaq Global Market Listing Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the SEC registration fee will
be paid at the time of any particular offering of securities under the registration statement, and is therefore not currently determinable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be
estimated at this time<B>.</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$400,000,000 </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158006g01m54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>representing ordinary shares </B></P> <P STYLE="font-size:75pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:75pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Morgan&nbsp;Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>SVB&nbsp;Leerink</B></TD></TR>
</TABLE> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g158006g01m54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158006g01m54.jpg
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M45-T=G>U0F%B8WBBLQ@S-C<Y6'6&E[:WTM7_Q  = 0$  @,! 0$!
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M:8..R7^"$"?S29$\ZA_.^+-Q&B//[ODK]:/+W\ON.G9']3M]CR?"64KW;O\
M<]3R?9^/&.I>CI/N]O'D30J\_?[D%Q^/V9=C]'.JBO?"OZ15.[V>]FLGQSQ[
M%BO'W?B^,;-#CG\*(^WC3-SGC,ZF'POX-ZFNLMG'?T\3D[!5["_YO/D!NS^G
MW^+OY<.]O\_;X]PGHUF"X]HRE)7U^%+[''XO)-;G]&HC=^&-LY?/Q=MO+6ON
M?;;]&AS^/P1DN/\ EW:9V;\9JSD>?X-ZAJ45W[^3WW9)BP>7^;S^P!UGS]ON
M]O3[_<[=;=/1I(\>T9:TWZ_#72CG\7>=CC_GSJ)7?ACVF<_%^V<15^Y]MR5J
M_P ?C\"L=W?\NW3137BW<A93S^P*U]6\*[^7W-5GB,M_S93FPS$[C.<?Z>%8
MSV^QUM4]),&KCOB_8X]_FM"//X_ E/Z.-1:Y\+/>=GGP-P&/YYX]DQY,F/Q>
MWVKL3,?;$Q]FFEF?$<Y+SF5^U[?F!DK[X\D-&5R PA.<Y[)0N$AP'<>7'Q87
MES+F>W=2U*[YSM4]-]O)X[,2DICZ7-L/Y^V8<XX_1Q'T1&HM;^$?ON[SY=W6
M5Q/T5$X^CQ'U1-*H@O3Z^9GZ9F9]=-3,<L]LV#SXG-L;"EDK[X4U(7*P%,]L
M_P"2EAZ14RA'^@A"48^YCK:)VAC4<>'%8]4Q]*ZE<2_')0N)F?MF>=1BWU?S
MU[GVW=6<M07O%^:OL#CZH K$A$?9 Q$?1&E7H&0VYN';5<JFI)*;1>#2L%_"
M .1.#^#L<*XUD^Q2\L,O) 49&H6A3[OF6Z2\L>/$9*/,$%?Q,_7Q>&Q-BWEE
M(]B >SP&M9^T-."\=9*BCM-K9B>V/2!B"89" &8[?8.0W'O'=>/Q6TK-N<VY
MGFF\BT]7Q?640R_(6[2IDTUJ\$,F4S),,EH4#7N4H]CC^"GD7_WG,_\ I16/
M_P!'KG?XTV__ !:C^=;7]GKT'^3'4#_Y'_\ Y?&_V^I0]1K5E:.FFCIIHZ::
M.FFCIIHZ::.FFCIIHZ::.FFJU?%%Y1[5XH:1US<M1$0(5AN>\JGKF2-G89$X
M@6 F*S=9LUR.$??;$;D5%5T%IL@MDUEL9PE.!O5<;>9L;IEMC%[IS61IY87G
M7IX2UD%@ATHDWJLTTA##$9.5P-@YD0()DH&9+B)$N?\ X1?4;<G33:& RNUS
MI*O9;>6+P%AUVI%R%4;>/R]MQ(49BH;$LH)$6-!P"LF1X^XA,%YS3OG*FE3_
M !E'XU5V7GHBS;JA87=;L531K:F+UP\;$(/+D7B!"\UV/]F>DE/S3.17!\,X
M5@MG*,>;"V;1VO=1N0MQV$H;6PSG8:&W"J2S(P#9 5B)A[0SNA?:DN^"YX["
MYUNNK6:ZDXB[T]#I_C[-ZMD=VU*>[BKXH,G%; FVK#VO,ULF@F%E8D[8RN5]
MO/D&8CF=W4&U<VCIIHZ::T'N4^\[=N#D+MR]6J4*(/D;S8@@1EDN.,0T#$2A
M49 0(&%?$T##Q0HH3*4I3EW+;A+WG(?><7WSM3$4,-MW$8^HD1!5"L;#@!@G
MV&J!EBPSB?5CG$9E]7, / B,1X(]5-V9_>/4/=^?REVR;[6=R*D)\S)52H5+
M3:N/H5Q]P(IU%*0$1$24@33[FL,BC_\ "4C[Y=_.*^;J0=J?O<?DC]NJ_P#)
M<_A-C\ZS1\)2/OEW\XKYNG:G[W'Y(_;IY+G\)L?G6:/A*1]\N_G%?-T[4_>X
M_)'[=/)<_A-C\ZS1\)2/OEW\XKYNG:G[W'Y(_;IY+G\)L?G6:/A*1]\N_G%?
M-T[4_>X_)'[=/)<_A-C\ZS4BN-''_='+#80NOM2PQ4@ZA3#]DLQV2!JI3(EY
MQ252]FET,NMB,Y2V][$"RA^5EGF5BQ0)A"5(3'MR;EP6U<>>0RS!6,]PUJP0
M)6KC8B)\-9,E$F7J/><R*DB4&TP'UU873;IIOKJIN!6 VJFTXHE9Y')O8]>*
MPU0RF)MY*W &*@X$_"@(9:MF,KJH<<3$;D/$+A[K?B#KU%5J7GG[=+MC/WO8
M<D,AF;MDFRE>4(0UAQ_$17X];KK<+ #$.LAM*6^61(2I)TD7QMO'>62WCD9M
MVXBM33)#0QJBDD4U%QS,EP,NL,XB7V"&".8@0%:06H/9#H_T=VWT>VZ.*Q,G
MD<Q;%;,]N.V$1?R]D(F8&![V>QXZO)F-+'J80)"98YEBVU]ITMNHAJW-5:[(
MX,;WOUPO-UOOB0\B:;39*RS\M6:GJXH/4D12:H9*%$05=/F(F<2+/*A8MT6.
M>F"XJ.=D%CY)(:R\XM:K-QV]L'0ITJ5'IWM^Y<76KJLV\F)Y9MVT"@%]A:6H
M[D0YL$P4@U@K@NT9XB(CG+/]'-YYO*9G+9GKYOO$XJQD+MK'XS;C$;8JXC&M
MLL93HNMU;<!<]CKDM!VFUT$^0EC!DR(IBQQ?V;L_2/B-P_$H3ES8^6^F+]J:
M8MN):ZVN/O\ .TNT10MB/1%.VAB4FBV9@%%6=P7'8."#?B+,"\5"(*&!-ZE&
MY<;C,UT\=NLMJ5]J9BAE4U952JLHHN5FG77+8JDI(2H_:H[&=AF+:QP#I S#
M5<=.MP;BVAUZK=,5=4+_ %.VGF=KVLI[3E\E7S5W$Y&L%UHUBR*[%MH6DCCB
M\J/,E1UL@DV5(8M+M8K=DW5SKYS<GM'2?+?8O%_7G'N8$K-+USI^?;I-YV'A
MLN2C)2R)FF"PY*5&9(B6Y23P^S+C"!V2O!A!AMY(,*_J:V&V1LG;.;7M3';E
MR&?2=FYD,NB;M''\@IJJW@(24HI%LK5VRHB.M8,S.8$ ^(Y#=O67K'U$V;8Z
MG9[IU@]C6E8_$8':MT</F<[ ML5[.0]K%JK%E8'6&S8[PLK4K(4%I4H>]K++
M^,W%G8G'NRV0^Q<LMY[_ *I,PC,=$U7<THFRDUZ2;/9*7-C64@MX\AYP5M8&
M!,#"CI:?=<7ZJ\,X:KC<FY\?GZU9=?:N$P-I+B8VUAU36"PN0D82581A8C!3
MW]_<93(Q$<1SST'T^Z<9W8]^^Z_U,WEO?&VJ@5ZV-W99'(,HV!<#)MKR!L)[
M#)8RGQ]BP@3(I[B@>VK_ (^?\I/Q2;MO#;I?*K</'OCK1MDR6NM7TG0TV[3)
MB6;CAAI3!<Y8 767"B&8*4KTC)/R;,VJ0E)PEB.1!1<6(&]9>?\ D[TQI87$
MAM?$9_<%['+R&3N9U,7$JEA$KL179$P(R]5A:Q7*/&I(RR7M:1CSMLB-_P#P
MC<OO'<[>I.ZMC;$PVX+& V[A]EVYQ-JR-9:[,MN7DD!L8-.Q1>\[ 6Y=8N,6
MB*=:NM16"4S6U[X,:NY![6OW)W</)2EU+6TI=*]5]NDCRD[ DTB&L$W(,-7-
MTHN1E7K3Y8V,9:<% & 6/EU39CA25"P*YD:.]LG@,70VUB-N7+>152L6<2)*
M0\;KD)64TX$%JBKRQDS!&3(+CD('@KPQ. S/1W;N^-RYSJ)NK?\ B,7@+.7H
MX[=!KLW:3,/5O7+ #EI-MBT>1XKUP$EI6B5]W:V61XH0\6./O)KG/IV&Y0[H
MYQ\D]92.SS['*4[7NA+:YK>GU*OQ=AE(&-;(C(]3H\CE]V*>*#\S:#\13@69
M.7D9-\TC$TW/GMM;)R[MLX?9.W,DO&+KJMY#.U(R-NW8;74]DBQD02^V&B)^
MLK\L'"E+5 #JH.G&R.H76/:M3J+NSK#O_;K]Q/O6L3@ME9.<!BL71K7K%*N+
M*Z8(+$G-8V+Y&&S7)4V++[!M/3S<"=Y;SKG*/DIP,Y ;"*W#-Z4B8R\:[V?+
MAM!VB8HTCBL.^RV1UM3JY(E<?>J?(,/F$'2(1I$V"1+R8:(W 6GWUA,)8VSM
MS?6!QXXA&9:VED,8HY.LF\OVF.ZM$Q$+&&4;BR$!6LP%)BI1RWOE717>.\:'
M4;J!T6WQG&[IN;1K5LQ@=Q6TBK(V\,^,<4KOD,E-ADIS&+>#&L=84YEQ++-A
M0UX3'WCR!R>\0O8?)Z3MW,W<VEJ3J+=UBUO6Z+HQJ)HRTPP9\E["O-IC<L2C
MJQQ!F1UN2C$L<0[ZA#DCY5(';W^X#VUL''[954V?A\S=RV%KY&S>S<NNQ+C6
MOR1[*SN5$$9240HE+&.!A?O*81L5/43KGG.HEG*=6-V;2Q&U]X7]OX_#;-&K
MAIBHES_ 4Y%';9(@6 @4V1LN87)D_B8 5#65;UX6^(WQWX]*Y,[EW]IKD+3K
M,5*P^\K*]=)^ORD3&6MT<B(FSE+4'D>2@XHI"XUB-:)"+DXXX,AS I[?PLQA
M-Y=/-P9_Y-X? YC 7*PJ=A*T4T/4UM6"%R0B(/N4]H3#"9(F*F 8QW!.=CYW
METEZ\[$V-/4+=F]MI[ZQ6198J[QR!9:]1M5D9(P96N.Y)?98J5F"2!0)J;80
MY3)A;84>ZK_R#Y?^();N%VJ-X7#CQI[16OXZW;0N&LWLQM[M4W)A5@W$?&6,
M=T61C<M.7.)AQ!6"F 1\QECECV)E[$4&/C8:A@-I;"J;QRN%J;@R^<OLJ8RG
MDH\E&JA9V0\C*Y"2V<Q3:XS(2,O+74N4QY3+/W=F]\=4NM^4Z2[9WAE=B[6V
M;@T93<>5V^?L^:R5RRG'NBO7O@2WUX&<K5K+6#!2'L]^P\+1^SI7#KQ2>)%L
MX]Z7U%8CN6/)'>==E.15'@DTO>5SQ> (R6(JE]D&+-$R#[0Y0)@@L6=%I$0U
MEAT:9)6M>'&6_/+NF.ZZN?S&6KAM7;N$L*V_=?[9A*?L1L4-J@LJS5C)"8&3
M0;W3/=!)&(CB9U57PC>F.3V-M/:MYW4S?^\:%C?N&IQB=XY:,PFO:9C<T\,A
M6L$"VJ<I==U>%P,@2[;)F>0'FQ[Q/-T[5U%:^$06M+S/4P6_\DH&KW1B$(0.
MBR5YZ2K;3T/)X4TYE\%ULPE#C'=*5X>5YN_9/:O.FN'Q>5J;U/(T47#H;<?:
MIDX9*:U@569%RO6.TXD!F"^CB.-7W\(?=NY-KY+I K;^9NXE>;Z@4<;E@J&(
M#?H'8H"=6Q$B7>DA:R"#TB8*>?HTC/$BWMMX7D+Q8XE:^W.OC55=Y*F)*][I
M%]G%F!QQ"G XVNPDV22!F'+>?#6.E0,C'&'3$Y71G9$4#!8Y^9T[P>)/;^Y]
MUW\/\H[6$\2Z.&+N))$8P;;#T@+/,(B<%\]; 6E%@H69]I+U77S>>Z%[YZ;]
M,<'NPNG^-WE-NQFMVJ\:[2U),E(H4[;#3[(UAJ)<$EZ&MM7**R>M/E6YZ=9<
M!MHZTOE(N\7X@7+6ZP\'/1$U9*9LNYKOM7N\4*2T4=!N,2)C;46'-,I4,\:P
MT<2RP\IQA>7L-NITV2WUC,E1NTF[#VI3:Y#4UKF-IQ0M4FD,B#H)83+327!0
M!2 S,<%'$S&I9MWHKN/;^9Q&7K];^IV7JT[M6Y?Q.X,K\=8[+UEL!CJ9 ]L1
M63;")630AI@!S(3W\%%E_5<:Z"UYO>U)E"=G['3ZZ/J;[<$_&YVS\5AD<?8[
M?%]CKT2Q?^C<=_L-3_MUZ\"=S463N3<$P!\3F\M,<1''$W['''V:07OM'].C
M\Y^[K.UI/8&_<G^2/VZ/?:/Z='YS]W33V!OW)_DC]NCWVC^G1^<_=TT]@;]R
M?Y(_;KDF8PM24(=PM:U82A"5Y4I2E9[)2E.,9RI2LYQC&,8SG.<]L8[])F(B
M9F>(CUF9]T1]<Z1CW3,1 ,F9GB(B(F9F?=$1],SJZ7A%X/>\.0SD/?-X-S&C
M].OJ9,;'D1/9]GW(!6<.)Q7Z[(L*Q6H\QK&?2L5I%2K+;@YL57IT)_!"*=WI
MU?PV AU'"2G-9<>X))9]V,IL]W+["Y_?+ GWUZIS',$#;"#'MGJ_I!\$C=F^
M#JYG><6]H;5*0;"G*$-Q99$\%$4J3@*,<AH^D7LBN"[2!M:C<4<,':_TGHK5
M7'>AQNM]04^-I]6COKJV TK>D):06A#9$S/RQ*G9&<F2DMMI?D9(DA_TFV16
M5-!CC#L\KYK.Y7<-]F2R]QMRTSYL$<Q"TKB9D4UU#$+0D)F9%:A$>Z2.8DR(
MB].-G;)VQL#!U]O;3Q-;$XRO\Z5IB3?:?,0++=ZTR2L7;;8$8.Q88QG8(*"1
M4M:PA-R?\3S2FD[[6]"ZX-CMP<B+I<:]08ZG0)Z7Z[39ZSS0< $[?IX++K0Y
M(AAJ5+J,2LFR/N-I%D$UY@MB43,=M=-\QF:-G.9$3Q& IU+%YEMX2-BXBLDW
MG%!!Q$D) '^=-@:XQ/<N;!"2M57U$^$!MC:67H;/P$JW5O?+92CAD8RFWOQ^
M)MY"VJFIF:O*[A U-;$SC*I,OF0PM\40:%B+-.JXU?VM9KP]-%Z9\01[=VR>
M;MDM&U=Z06X9F+5J>S;,M$ !2ZPU&Q98)$;58*<A9$6-S/EV.NL!L/(A(T>L
MLQS  ZL$>T=(;_S>8V$.%QVS*];%X1^(2WXUK8RJ]ERU+&@P66GH>LF^ :U@
MC*)>PK,LEA?-[?/GH;LW:G7 MX;@ZOY#);EWC2W7<K3MG(;AR5*OB,<"*S4G
M7QM.Y4>NO[:V]1!0'%2N% *X(7,'+'2K6H=*Z3\:;0U&T-5:Q4:@)QILQ\K$
M54A1@[=D(!VZ,:3+$.&'EJEW8X>&;?4>2HK(R //]0IG*M;8RV9S/1O.W<Y:
MLV[9[BK+4ZT/84UQ;B2 5#  $*AA.D86,#W2SCU[M23';6VCM#X6NS</LO&X
M[%XM?3S(/LU<:<M7&08&YEN99,FN9-HD+J"<N9+/&*>?FR/,W^0?"#P_>7]^
ML=EN!M9QMR'(]P72PZTV=&PMO%D8)M "0;C#AGR,7[]AV1V05/SU?S-C#"C
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MY.DR,;'-H+F*_K82+H-4!]+RJ6W([&N_O(XV,=5W0\MFL5,S#7_,F,.JPXW
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;FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g158006g19v99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158006g19v99.jpg
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M#<A'GG$)DYQH>?<KG'M;33LA+RP\\6$)8;VU96EA^2HE.:<DI9C.K4<_\'(
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MNW9G><B1EP3HHLR7CY,:C#2RIS&%8<=Z/(;DOI=8=?=U1[865*D.QG7-".J
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MT2I5(9"CDLDF:<I!+6YO5NL71-+DD<B7-O>D@]VW7^^NW2QQYJF'(\^.O31
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MV0.<N#.DWOT)3>!]47"[@'C7(?-[3?TPU\%7SZ.!Y]3@<;('.7!G2;WZ$IO
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MJZ.,]K\16G-0.96G3YAR=9D?6=Q?VF"MJ1R6L[2:F)<5Q:MV;VD):4U8,"8
MP&N!9HKFC"&Y98[6ONKAM77L5H=OUVA6AAUMAV:XMM#KH46T%#3CI*@@%1!#
M9 R'&1[5><QGBB-@O#%WQ1+BOS(UGCMR'8L93:'WDN2&8^BVITAL*!>"O9$
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M=GTPB&^WUB<J7[6U]V(CYY3>-O/M7NV?12Q_\AIPQL*<T,0]*MOE:EO^V$>
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MST@?+Y!Z2IOF2.9&+.@+\G3@\POC@V,_#+7EZYML5L<O_P"WIH_M[\_06_\
MN50=DV0/_<?%I[4!9_\ ITX/,+XX-C/PRUY>N=ZLCGAZZ/OE^@])5&^=(YC8
MN\'K\2G!YA?'!L9^&6O+TWJR.>'KH^^7Z#TE3?.D<QL7>#U^)3@\POC@V,_#
M+7EJGO5$=\/71[R@(?2--\Z1S&Q=X/7XE3P=X?QO[&GAAKRU-ZHCOAZZ/>4!
M#Z1IOG2.8V+O!Z_$IP=X?QO[&GAAKRU2ML4\<O;_ "]]'EO?GZ#TE4;YTGF+
MBWH#GDZG@[POC?V-?"[7EZYWJ:.>'QH\Y0$'I*F^=)YBXMZ YY*G!WA?'!L:
M^%VO.*;U-'/#XT><H"#TE3?.D\Q<6] <\E3@[POC@V-?"[7G%-ZFCGA\:/.4
M!!Z2IOG2>8N+>@.>2IP=X7QP;&OA=KSBF]31SP^-'G* @])4WSI/,7%O0'/)
M4X.\+XX-C7PNUYQ3>IHYX?&CSE 0>DJ;YTGF+BWH#GDJMP=87QP[&?AAKR]-
MZFCGA\:/.4!!Z2IOG2>8N+>@.>2IP=87QP[&?AAKR]-ZFCGA\:/.4!!Z2IOG
M2>8N+>@.>2IP=87QP[&?AAKR]-ZFCGA\:/.4!!Z2IOG2>8N+>@.>2IP=87QP
M[&?AAKR]<VV*6.7OM6U\:/.4!#Z2IOGR1QX&Q:/_ -"YY*G!UA?'#L9^&&O+
MU+>HX[X?&COE 0^D:C?0D<QL6=!7Y.G!UA?'#L9^&&O+TWJ..^'QH[Y0$/I&
MF^A(YC8LZ"OR=.#K"^.'8S\,->7KG>HXYX?.CSY?H/2=3OG2>8N+>@.>2IP=
M87QP[&?AAKR]-ZCCGA\Z//E^@])TWSI/,7%O0'/)4X.L+XX=C/PPUY>I6V*&
M.7_]OK1U;W\@(-O^\J;YTGF+BWH#GDJ<'6%\<.QGX8:\O6<0[85)+D6ZZV/M
M76G&=7:[$W<K0YT7R>[=93T3I>ZZS(-=TI8_H1O0>F.A]%Z&9N-UN!;6E,V8
M(]OT-WX5Q!!VS/:]V-(C;9HY:6AMP1IZ.8ST<\LQGQUU;9^2O/O6W>HVR1@B
M[;GT-O\ 4Q]Z?M&V:6U[=N4N[7IZ*M#3T=+15EGD<LXW@7-_#OBKB>7>95HG
M9TLP&9LES^FB>/77'Y'&+"<AB_#W1;EY*F\"YOX=\5<3R[S*J[^UE^ [I]+$
M\>K<#;%G._#O1KEY*F\"YOX=\5<3R[S*F_M9?@.Z?2Q/'IP-L6<[\.]&N7DJ
MGO 6<.'C%/$\O\RIO[67X#NGTL3QZ<#;%G._#O1KEY*EM@"SC:^W;/&*=NW;
MM_X'E_F5-_:R_ =T^EB>/3@;8MYWX=Z-<_)5L)UV%C5J]N62G=VU28]7.68-
MUUS%A[3*+FS'=RIJFXNJVY:PA%MRMC:7S_@X2-I8A)O;:*W98M!K9BPJRW;F
MFL,ST-VG+U-0'8V43**["&U9ND_Q5]UGV6E[!9]O(CM2/R6-DB6_?9,G9 LK
MK^)L_5YU4:X:5SSN,:['=.4< YW&)&EG0"/SK*/\'-)U];8 \Y![8<\XJM>]
MKVO>S1+[;=A6O85NTB[E[7O:]NY>U[VOVJW]_6R? =T^EB>UQ?X=<7@;XM'%
MC##H]K^+7/BY/X*N0; %G*PML.><5!%:U]J]FB7VO;;[5]J]D6WV[7VK_P V
MW3?ULGP'=/I8GCU(_(WQ:#GZ\,/#Y1&N>?\ X0KGU/\ YRX>,4<42_S&F_M9
M?@.Z?2Q/'IP-L5\\,/=$N7DZND/[G\S*-8E Y9_QDF;Q'EA6J$,=E2Y82FN.
MUCC$J,\+<0J/ #;N60:N2%F#M8(E!5KW':J]G:T!"BW8KDIP).@E<B*A!5EJ
M"EI+BDI)XR$*('$D\59&OR-<3%UL/XSL3;)6D.K:@7!YU#9(TE-M++"7%@9E
M*%/-)4<@7$@YC]!FEW2MB32/C5'CC%3-8@ ^@*Y3*G ))THFSX65<LQYD+@6
M67<T=MV:!O;B E-C.F,$E;DI(!'"-^#XFQ/=<57%=PNCVEEI)C16R1&A,DYA
MF.V2<O:+CBB77E *<4H@ ?LS8_V/<.;&]A:L>'HN@#H.7"XO!"KA=I:4Z*I4
MYY*4Z1&:@PP@)CQ6U%MAM *RKTC7G:]S58'VMOR_IO2E2I2E*4I2NAE7\6)'
M_4+Q_=ZBE2GC';'WUJ#!/WOVK\45^J#5$<9[2?NK:7QCM?B:R)R^Z*W\?_AE
MUTHG\%^VO[ZX,_\ C'["?QJRK9K2I2E*4I2E7%*4I2H6,+$,981@$878-S 6
M$&XR[#M>X+C#:^Z#8=@WN&XK6W5K7VMO:O2E3I2E*NCC/:_$5X6V2_\ R&-0
M_P#99E_WSC->UV.O[];!_P!I>_V.37RC9X_Y(\;_ .;8_P#YG!K\CVG+ SEJ
M'G#Q"VMV6-!K+!Y-.3QMD5>IL\KDD9*3&GMC)%X_MN[P[+>F0@1I$81FF"#<
M(0#%>P;_ *FQ!?&[!"9F.-(=#TV-"2'93,-E"Y)4 X])?_-,M(T25+7J&K,@
M:Z_FK@?![^-;M)M;$EV,J+:9]V68]NE7:4\W 2VI<>+;X7]TR9#H< :;:!4H
MC( YUL.?:&-0\(E[G%TT33RU(DFCO"VZ1L#RR@;G,UI/EY1C^J0NKBWO<7BQ
MEH!-]W)9:VLD?3J(=+$9KKT>..P4VA!QI89D1N2J4J*M4-J8Y'?9>+C8=3$(
M82MIM;,F2-W0LH\5QY]29<58:T9#15V[SL1XVM-SD6]NW(N335UE6IB=#E1
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MF'L"TAXT]Y456?&*(1W,L2 U/!I*!*>:1(([GC(39(CT1J%>H L;U#:L:EB
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MQ%>%MDO_ ,AC4/\ V69?]\XS7M=CK^_6P?\ :7O]CDU\HV>/^2/&_P#FV/\
M^9P:_(_IJRXR82R0XS=_8AR1"?B[-$*)9;HTR]$M=<BXFF,$90/2-2X-@5,=
M"[2%&9(BB5@%8F0*ZR(I0KZ"09^IL16IZ\V]N$P_N9:;E9YBG@M2%H:M]TB3
MGBRM+;NC(+4=8CE2"@/%&F4HS4/YJ8%Q)$PI?'KM-AF>RO#^*K4F(6D/-/2+
MYANZ6>*F4TX\P%P1)G-&<E+@=,0/;4E;FBA7M]DUZ8A?XI!S,QX>8I7/T4[9
MWR=+T.+8J>G5HV%^4WC<@C#DJG+<U%JHE 2(QCYN@#[CU:TO3)&"2'::E)W
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M@J40$@$DD@  #,DDZ@ -9)U 59*5+4E"$J6M:@E"$@J4I2CDE*4@$J4HD
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MQ]&U'K5V0?C%/@"%Y2F^3L(_$4CZXW/S>G9;['-^#7)Y?ICZ-IZU=D'XQ3X
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M_P L[,C.'V[ZRNW+RO+J"J\LLA)C@E*3'==((T)SB<]M0D'3:#3K@0XK2?\
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MX\-'T33@:CXQ3]4Q_22F\"@\*T7(?;G=IOZ'FN/#1]$TX&H^,4_5,?TDJIO
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M?W0!%[6VKZ8'_N\*S=_-_P# 5-XF3SE8\%N>?4X9%OY@S/K$QZ'J7J@&+>#
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M7J;RN**@(398)E<GB$)IG&W]@!3F1SSS]B?T>7/, 9$\A/Z]8S%3M<<JR!2
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M8K;G'-JE X(%)Z)<A6XJQ&E6(EB4T9"E(K2GX\+/3*4YP!DGD'  :2: 99@
MC#>ULZ-C/ CB$.-V=+C;B4K0M%SNBD+0H!25H4F<4J2I)!2H$@@@@D&M1W\H
M?9J8=<8?Q8XR^RXMIYEW#F&FW6G6U%#C;C:[(E;;B%@I6A0"DJ!2H @BNX>-
MDPV2:.I4BZ091D+$B7F]+H5CQA?&#8E6G]269_Z"D4+<;$%*3>H4CCSUT,D8
MQ]27YF<=STFZ(3C\+.QUL>R%+0Q;8[ZVQI+0S=[BXI"=M>8S6E%P44C;X\AG
M,@#;6'F_TVEA.S)V>]G6$VV[,Q#-B-/*T&G9.%</,-NKW-%F:#:W;"A*U;CG
M0I6BDD[FF17\MJD,K7UB#93]D+=%R!K:\U+'%R=%2="UMR#$^)%BYQ6K% 4J
M1&@2)\=F*%BI4J&%,F3IRS#CU @DE $9>P;Y'-C+ 3:''7;.AMMM*ENN+NET
M0AM"$Z2EK4J>$H2E(TE*40$I&9(&NM=G\H;9KD/,QX^*W7Y$AQMF.PSAS#3K
MS[SJPVTTRTBR*6XXXX0A"$)4I:R$I!4<JHJ-E9V0-(H/2JLY')E28XU.I3*,
M68@)4)U!(Q%G$'DF8]"84<48$19I1@0C+&$0!AL*U[6E.Q?@-24J390I*@%)
M4FYW4I4DC,*21/((((((.1&L51?Y1.S0TM;;F+E-N-J4AQM>'L,H6A:"4K0M
M*K(%)4E0*5)4 4D$$ BNSD&R?;(Y$W92PRG+CS&GQ&!(8K9I!AW%;,[)2UZ-
M.X(3%+<XXX3+" +$"I*N2#-)"%0C4IU)-QDG%C%B8V-=CZ4TE^-:F9#"RH(>
M8NUS>:44+4VL)<;N"D**'$J0H G16E23DH$#8F;/^SC;I+D.X8EE09;0;4[%
MF88P[%DMI>:0^T7&'[$AU =9<;>;*D@+:<0XG-"DDVSMLI6R(L+FO97W,S@R
MO+4K/0.C2[8DQ,W.;:N3&"*4HUZ!9CHE4C5IS0B+/3J"BSBC B 8 (K7M5FM
MC/ #[;;S%H;>9=0EQIUJZW1QMQ"AFE;;B)Y2M"@04J22"#F"16.3^4)LVPWW
MHLO%+T65'<6S(C2<-X;8?8>;44N-/,NV-+C3B% I6A:4J2H$* (KK]]AU^</
M/^S'#O-]63>MP+\!_P Y7;SZL/"-V9>>'\P87]"UV3GLI>R),BDM&\YE<&A6
M<A;'0I*YXCQ*@4FMCTW)7=G<2R%6.2C1H79I6HG1L5A#=.O;E:5:E,-3*"C1
MXVMC/ #R2MFT-NH2MQI2FKK='$AQEQ33S94F>0%M.H6VX@G20XE2% *20,S_
M .4)LVQ5I:E8I>C.J98D);?PWAME:F)3#<J*^E#EC2HLR8SS4AAP#0>8=;=;
M4IM:5&W1[*ML@[@K2H$&;U"Y>N4D(T2)'BG$"E6L5J30DIDJ5,3CL9RA2H.&
M H@@H S331A++"(8K6O9>QA@)M"G'+,E"$)4M:UW.ZI0A"05*4I2IX"4I )4
MHD  $DY"J-?E$;-+[C;+.+%O//+0TTTUAW#+CCKCB@AMMMM%D*EK6HA*$)!4
MI1  )(%<+-E6V0=O5JD"_-YZ%<A4'HUJ)9BG$"96C5IC1$J4JI,=CL!R=0G.
M ,H\@T #2C0"+,"$8;VL1L88"<2E:+*E:%I2M"T7.ZJ2M"@"E25">0I*@04J
M!((((.5'?RB-FEEQQE[%JVGFEK:=:=P[AEMQIQM12MMQ"K(%(6A0*5H4 I*@
M00""*N5^RE;(FUDM:ASS*X-R=\;NJ[*>OQ%B5(2\-/3RYKZJ-9JC')8'!NZI
MMCDW=.I!')NGF]<DZ+TPD4%EU1L9X =+J6K0VXIAS:7DHNMT667=!#NU.A-P
M);<VMUMS07DK0<0O+16DG(]^4'LVQTQUR,4OL(EL;IBK>PUAMI,F-MST?=$=
M2[&D/,;?'?8VULJ;VYAYO2TVUI397V5_9 2MNXL["!M7W%[BQ;AT.T+:L+<W
MV\>VVA;6U?:OV]KM[6U5QL78$/%9 >U<KL?_ +^L)_*+V9AQXO(UY:\/X8X^
M3_B7C^2N-]FU_P##W_LPPYS>U.];@7X#_G*[>?5'"-V9>>'\P87]"TWV;7_P
M]_[,,.<WM-ZW OP'_.5V\^IPC=F7GA_,&%_0M-]FU_\ #W_LPPYS>TWK<"_
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MD2DB82&Q0"QU=)[&V)Y#CCKUT4MQUR^NK)BP0 K$EF8P_>$H2(P2TU(LT9B
MRPVE#,%EI!@-Q7$A=9#,DJ))<))+Q)*4<<AI+#N7L<@%-(2@ 9!  T FNY*S
M[E EW.?BW9AZKJRF^RY:.!P TQS6M*NR]K?G4)L8&6Z2IN6VNJ12QP IDJ<X
MPX13J'IA18W>1LC8L1-<N"9ENW8\B,)$A6'L.J7*?AO;HB7&6%6HIEW>,_FZ
MQ>)*7;HTM3A1+&VN:=Q/E!97I-Z9"0I6T,9J4@A2'%?F\E.I(S2ZK-Q))R4,
MSG9M><,GLX @120L70T;2D3&+V&-NIR ;%=ZNS.;8H=&A8>V2%L^R)[LCDR
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M+JI-*$KPND:B^Y I;SFI?)ED7&Q4(6,M'/+2.K4  %#1&67$1F<\^+4?:RS
ML*SVPI)T$9J)65%1;.DK2)()"\AEE\O$"#!Z(V0]MC;XJ)D>75JU]92G0U*D
MCF,W4YD>6[.>3FM''&(Q C;7B/M;SB@N K7)[2()\\)##D;B-E5IS'H*%[/(
MZU9G7VLE'4,N($99\9_53^YR1J0 #EGFH9C022<L\B0LJR_1!RX^+.31C;.3
M?)9_+7O3"^3#5=(9 JR7B?.KY)X<4PXS2WTNMT9CT4?ITPJ&2SV5&\E%/T*>
ML5)8LU0.5+G]3/2VQ.TB+6I62LR2G-1.85J&C['+(D<>1S!&H'//+732;R2
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MIZ=J:&-?(U+"PQ#&R_%.!&\R+(U[6KCKE+G)F59'A65EJI0VX7DTZ62%]97
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MT62IO4)Q4@KEM]J#<PK19E*R5Q(?)U'D2Z3Q'V@YQ<6V>VNOJJ$01A", @C
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M[_MWVV0UZN/C^7MU)).69)RU#,\0Y!7:TJ*4I2E71QGM?B*U7G0L9N%,NEE
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M"\),B9-M\QV6&)^VJ-MG88N$=IPZ6DXC;\,1DJS6 &I4D(2AQ0=-O5-_)?\
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MF]1.>:L@-%7UO3)DR),G1HTY"1&C()2I$B4DM.F2I4Q824Z9,G)" HA.G)
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M""%':X@@N9NKVM>U[VMM6O;NV9_(1W.L_P!ODSIM)!!*AJ/:K-\1L"UBAR!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g158006g81r14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158006g81r14.jpg
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M#66'AYDEQ:L.,M^*7=,=UU<_F,M7#:NW<)85M^Z_SF$I^2-BAM45E6:N)(3
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M--,?:%$#$9R2442^M+; XP[.%NOOO.*2VTTTA3CBU)0A.59QCK^2;V"1FT0
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M-L;M;AG;CQ%?*MV_D5Y;#F\[ 31R"B6:[*X0Y4&0DI<]KH8N>V.0GUT@M_\
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MT*TBZVOW]MU]GUX]?2.*]O="KY3_ +<=3'Y/T_I3]NJS]E#]3_?H]T*OE/\
MMQT^3]/Z4_;I[*'ZG^_6RO\ ,R]$7;.3>_-K/L^H#UKIF.JC+BD? $F]FVT(
ML(A*L?S7UP^O;$*C&>_"F22?>[\)SBD^M]Z%8/$X\2X*[DCL%'=S)*HUS$HX
MYGY/B7$E/WQ'U^GIGX,.WAC=6>S,KY''80*03,?M'92XHQ*)]Q>#CK 1](F6
MMU/KF77;NCIIKYO.H89=?<[_ "V6W'5]V._/@;3E:N['QY[L9[L?'GIIJO\
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M]^&FGUWW]6CQ0^]+/_XC^FFG+YV?4J[3_P#1'_V-4.FFGLTM_D<U-_5G0_\
MXM%=--1(X,?3OD__ %VS/Z7+]--<=W?5R<6_^@6;]$LO337VDMD;VW1OW9>H
M=7WJ#U)5M8#AM2EA<JP-KL<L63AAI[+ DNO ;;62EE(84.X"H<<9EU9#SY24
M---,CO75MMU_MSBB?;MPW7:A\UNB 9PFQI&!AXG(=FISBW8:&$<>8!=,R3A)
M2DO*\QL<='^C[\M-6V]-->0/R.#D*WR&WS79AIT.6@-S;1A90-YM2'1)&+N\
MX":,ZA>4K0XP2PZTM*TI4E2<X4G&<9QUVMB[L'C,<8'R!T:A#,3S$B5=<C,3
M$3$\Q,>L3.N4;^T8\]=[@GN\W9[O3_.\8^?H]^F8]=CY3/X,?M=9_FI^M/Y_
MLUB?%$/J3^+1Z['RF?P8_:Z>:GZT_G^S3XHA]2?Q:/78^4S^#'[73S4_6G\_
MV:?%$/J3^+1Z['RF?P8_:Z>:GZT_G^S3XHA]2?Q:/78^4S^#'[73S4_6G\_V
M:?%$/J3^+1Z['RF?P8_:Z>:GZT_G^S3XHA]2?Q:]1/L4M2.Z8[+_ (BULP-P
M.4LFO"-J2F"&<L%ON[=L<WLF.<*;4E*L.,0-FB 6L+3A:!0QVU]ZD9SGDG?N
M0]I;MS5B"[A79&H'$\Q$4E+JEQ/T2Q1E/N[BF8]-=(;+Q88?;6+I"/;/A,L'
MZ<3)6W,L\E]^!:(?@&(]VK3.HAJ4Z.FFL&3^ELA]XE_H[G3352'#'4VV;?IQ
M4[0^0E@UC'.6N<"?K@U0B+/&J(&9C<N2#"I&2#6*04AUM#V&T9QWLH5XLYSG
M'334Z=*\;(?4UBLE^F;;8-D[-MK"0YJ[6;RVR, )6.XH&-!;<)R&.ZH,+#N'
M33,I9 "%$R*(QY"VFE%J[1T5J^];AO0$[(2A6X+ %/R(!8PS(\,Z$78#$CA.
MLYRX0VXNPOIRM_"5)0.UW8SE2\]--?NR]'Q6RM@ZBV ;.R$89J.8D)B/CQ1A
MGAIAP]^&(4R8Z]G#HZ&EPS6,*8PI2DO+[\8RE.>FFD-M3B^Q=MAC;=H>Q+)J
M79:(YN)/GH(4:5!F06&D#LIE(<E\+!3B!6AQ%X4;Z-X<0+#P:WA6GL--))[B
M5:[A-5>1W1R!MVSHRI3P5CBZ^Q5X&H1JY./7A;*B\ D22G&W$X4P1EI+!2AG
M7FV2AU.>8EIIY;MHZ*NVW-8[;*G9 &0UDU)-!1# PS@4IB10\C.2GW,X?8RU
MEY6<>5A7CQC&/@^_G+32AW1J\'<^M++K62E2X4*R>Q_.DP6&22A<P\_%S[7E
M,D92TOSGHML=S"LX[FG5J3GQX3TTTL*C7F:C5*Q5!B'2QZQ7H6O,%OI0AXIF
M%C1HUHAY#?P$.O(&2XXE'P$K5G"?>QCIIIKM,Z.B]-&;',C9V0FE;&N)EP,0
M<,./B-?+=*=R$-D=2LOM(R4K&'7?"M6$I^#CW^FFBX:-BKAN76VY"9V0#DM;
M@R0(<*P,,X%)ID69!K+A)#F?/84UF06K&&DJPORTI^#WY5TTTW>P>+"YW91V
MWM8;1LVG[[-!- V(R'CPYV&G&F&AF$.&0I9(#:G7&PP_4H<)>"?>$',P&V=A
MXIYIKJX[BE8IBZTFZ[AWI;-J$Z]G!['5XK-=A*E$"RXA AC#Y P#TCEYOU0
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EIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
